WO2011133637A2 - Compounds and methods for kinase modulation, and indications therefor - Google Patents

Compounds and methods for kinase modulation, and indications therefor Download PDF

Info

Publication number
WO2011133637A2
WO2011133637A2 PCT/US2011/033192 US2011033192W WO2011133637A2 WO 2011133637 A2 WO2011133637 A2 WO 2011133637A2 US 2011033192 W US2011033192 W US 2011033192W WO 2011133637 A2 WO2011133637 A2 WO 2011133637A2
Authority
WO
WIPO (PCT)
Prior art keywords
fluoro
formula
lower alkyl
compounds
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/033192
Other languages
English (en)
French (fr)
Other versions
WO2011133637A3 (en
Inventor
Jiazhong Zhang
Prabha N. Ibrahim
Wayne Spevak
James Tsai
Todd Ewing
Ying Zhang
Chao Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plexxikon Inc
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44816304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011133637(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SG2012076584A priority Critical patent/SG184874A1/en
Priority to RS20171089A priority patent/RS56588B1/sr
Priority to HRP20171660TT priority patent/HRP20171660T1/hr
Priority to CN201180030925.5A priority patent/CN102947305B/zh
Priority to EA201290973A priority patent/EA028105B1/ru
Priority to AU2011242778A priority patent/AU2011242778B2/en
Priority to PH1/2012/502103A priority patent/PH12012502103A1/en
Priority to GEAP201112896A priority patent/GEP20156251B/en
Priority to EP11772612.5A priority patent/EP2560972B1/en
Priority to MX2012012197A priority patent/MX336056B/es
Priority to LTEP11772612.5T priority patent/LT2560972T/lt
Priority to SI201131348T priority patent/SI2560972T1/sl
Priority to DK11772612.5T priority patent/DK2560972T3/da
Priority to SM20170458T priority patent/SMT201700458T1/it
Priority to NZ603087A priority patent/NZ603087A/en
Priority to KR1020127030470A priority patent/KR101799126B1/ko
Priority to CA2796998A priority patent/CA2796998C/en
Priority to JP2013506264A priority patent/JP5808793B2/ja
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Priority to UAA201212061A priority patent/UA109128C2/ru
Priority to BR112012026927A priority patent/BR112012026927A2/pt
Priority to PL11772612T priority patent/PL2560972T3/pl
Priority to MA35365A priority patent/MA34229B1/fr
Priority to ES11772612.5T priority patent/ES2641643T3/es
Publication of WO2011133637A2 publication Critical patent/WO2011133637A2/en
Publication of WO2011133637A3 publication Critical patent/WO2011133637A3/en
Priority to IL222498A priority patent/IL222498A/en
Priority to ZA2012/07898A priority patent/ZA201207898B/en
Anticipated expiration legal-status Critical
Priority to CY20171101332T priority patent/CY1120554T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • compounds are provided, as well as various salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof.
  • the compounds are active on one or more protein kinases, including Fms, Kit, Flt3, TrkA, TrkB and/or TrkC, including any mutations thereof.
  • compounds are active on Fms kinase.
  • compounds are active on Fms and Kit kinase.
  • compounds are selectively active on Fms kinase relative to Kit kinase.
  • compounds are active on Fms kinase and Flt3 kinase.
  • compounds are active on Fms kinase and one or more of TrkA, TrkB and TrkC kinase.
  • Also contemplated in accordance with the present invention are methods for the use of the compounds in treating diseases and conditions associated with regulation of the activity of one or more of Fms, Kit, Flt3, TrkA, TrkB and TrkC, including any mutations thereof.
  • the use of compounds for therapeutic methods involving modulation of protein kinases are provided.
  • the compounds are used for therapeutic methods involving the treatment of a variety of indications, including, but not limited to, rheumatoid arthiritis, osteoarthritis, osteoporosis, peri- prosthetic osteolysis, systemic sclerosis, demyelinating disorders, multiple sclerosis, Charcot Marie Tooth syndrome, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, global ischemia, ulcerative colitis, Crohn's disease, immune thrombocytopenic purpura, atherosclerosis, systemic lupus erythematosis, myelopreparation for autologous transplantation, transplant rejection, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, renal hypertrophy, type I diabetes, acute pain, inflammatory pain, neuropathic pain, acute myeloid leukemia, melanoma, multiple mye
  • Li is -C(H 2 )- or -C(O)-;
  • R 2 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally substituted with one or more R 8 , -N(R 9a )(R 9b ), and -O-R 9 ;
  • R 1 is fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • each R 4 is independently selected from the group consisting of fluoro, -OH, lower alkyl optionally substitituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro;
  • each R 5 is independently selected from the group consisting of fluoro, chloro, -O-R 10 , -S-R 11 , -S(0 2 )-R 12 , and lower alkyl optionally substitituted with one or more R 13 ;
  • each R 6 is independently selected from the group consisting of fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro; or two R 6 bound to adjacent carbon atoms of the heteroaryl ring, taken together, form a fused cycloalkyl ring;
  • R 7 is cycloalkyl, lower alkoxy or lower alkyl optionally substituted with one or more fluoro;
  • R 8 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 9a is H and R 9b is selected from the group consisting of (i) H, lower alkyl, lower alkyl substituted with one or more fluoro, lower alkyl substituted with lower alkoxy or lower alkyl substituted with hydroxyl and (ii) cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, each of which is optionally substituted with one to three members selected from lower alkyl, haloalkyl, lower alkoxy or fluoro; or
  • R 9a and R 9b together with the nitrogen to which they are attached form a 5- or 6-membered ring having from 0 to 1 additional heteroatom selected from O, N or S, each of which is optionally substituted with one to three members selected from lower alkyl, haloalkyl, lower alkoxy or fluoro;
  • R 9 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy;
  • each R 10 , R 11 and R 12 are independently lower alkyl optionally substituted with one or more
  • each R 13 is independently selected from the group consisting of fluoro, -OH, and lower alkoxy optionally substituted with one or more fluoro.
  • R 3 is fluoro.
  • the salt is a pharmaceutically acceptable salt.
  • the invention provides compounds of Formula I or any of the subformulas as described herein, or a pharmaceutically acceptable salt, a solvate, a tautomer or a stereoisomer thereof.
  • compounds of Formula I or any of the subformulas as described herein, or a pharmaceutically acceptable salt or a solvate thereof there are provided compounds of Formula I or any of the subformulas as described herein, or a pharmaceutically acceptable salt or a solvate thereof.
  • the solvate is a hydrate.
  • R 2 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • Cyi is cycloalkyl optionally substituted with one or more R 4 , phenyl optionally substituted with one or more R 5 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 6 and optionally substituted on an available nitrogen atom with R 7 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, and heteroaryl is pyridinyl or pyrazolyl.
  • Cyi is cycloalkyl optionally substituted with one or more R 4 , phenyl optionally substituted with one or more R 5 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 6 and optionally substituted on an available nitrogen atom with R 7 , wherein cycloalkyl is cyclohexyl, or cycloheptyl, and heteroaryl is pyridin-3-yl or pyrazol-4-yl.
  • Li is -C(H 2 )-. In some embodiments of compounds of Formula I, further to any of the above embodiments of Formula I, Li is -C(O)-.
  • Xi is N and all the other variables are as defined herein.
  • Li is CH 2 , Yi is CH and R 3 is F.
  • Li is CH 2 , Yi is N and R 3 is F.
  • Xi is - R 1 ) ⁇ R 1 and all the other variables are as defined herein.
  • Li is CH 2 , Yi is CH and R 3 is F.
  • Li is -CH 2 - , Yi is N and R 3 is F.
  • Cyi is cycloalkyl optionally substituted with one or more R 4 .
  • Cyi is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl, each of which is optionally substituted with from 1 to 3 R 4 . All the other variables are as defined herein.
  • Cyi is phenyl optionally substituted with one or more R 5 and all the other variables are as defined herein.
  • Cyi is 5 or 6-membered heteroaryl optionally substituted on an available carbon atom with one or more R 6 and optionally substituted on an available nitrogen atom with R 7 .
  • Cyi is 3-pyridyl, 2-pyrrolyl, 3- pyrrolyl or 4-pyrazolyl, optionally substituted on an available carbon atom with from 1 to 3 R 6 and optionally substituted on an available nitrogen atom with R 7 .
  • each R 6 is independently selected from the group consisting of fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with from one to three fluoro, and lower alkoxy optionally substituted with one to three fluoro; or two R 6 bound to adjacent carbon atoms of the heteroaryl ring form a fused cycloalkyl ring. All the other variables are as defined herein.
  • R 9a is H and R 9b is selected from H, lower alkyl, lower alkyl substituted with hydroxy, lower alkyl substituted with lower alkoxy, lower alkyl substituted with 1 to 3 fluoro groups, cycloalkyl optionally substituted with lower alkyl or one to three fluoro, cycloalkylalkyl optionally substituted with lower alkyl or one to three fluoro substituents, heterocycloalkyl optionally substituted with lower alkyl, heterocycloalkylalkyl, arylalkyl optionally substituted with from 1 to 3 members selected from lower alkyl, fluoro or haloalkyl and
  • R 9a is H and R 9b is selected from (i) H, methyl, ethyl, t-butyl, propyl, isopropyl, 2-butyl, n-butyl, 2-hydroxy-2-methylpropyl, 2-methoxy ethyl, 3-methoxypropyl, 2,2,2- trifluoroethyl, or 4-methoxybutyl and (ii) cyclopropyl, cyclobutyl, cyclopentyl, cylohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexymethyl, benzyl, 1 -methylbenzyl, 4,4-difluorocyclohexyl, 2-tetrahydrofuranylmethyl, 4-piperadinyl, 3-pyr
  • -N(R 9a )(R 9b ) is 1 -piperadinyl, 4- morpholinyl, 1 -piperazinyl or 1 -pyrrolidinyl, each of which is optionally substituted with one to three members selected from lower alkyl, haloalkyl, lower alkoxy or fluoro. All the other variables are as defined herein.
  • L 2 is -C(H 2 )- or -C(O)-;
  • Cy 2 is cycloalkyl optionally substituted with one or more R , phenyl optionally substituted with one or more R 17 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 18 and optionally substituted on an available nitrogen atom with R 19 ;
  • R 14 is selected from the group consisting of cycloalkyl, lower alkyl optionally substituted with one or more R 20 , -N(R 9a )(R 9b ), and -O-R 21 ;
  • each R 16 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • each R is independently selected from the group consisting of fluoro, chloro, -O-R , -S-R , -S(0 2 )-R 24 , and lower alkyl optionally substitituted with one or more R 25 ;
  • each R 18 is independently selected from the group consisting of fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro; or two R 18 bound to adjacent carbon atoms of the heteroaryl ring, taken together, form a fused cycloalkyl ring;
  • R 19 is cycloalkyl, lower alkoxy, or lower alkyl optionally substituted with one or more fluoro;
  • R 20 is fluoro or lower alkoxy optionally substitituted with one or more fluoro;
  • R 21 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy;
  • each R 22 , R 2"3 and 24 are independently lower alkyl optionally substituted with one or more
  • each R 25 is independently selected from the group consisting of fluoro, -OH, and lower alkoxy optionally substituted with one or more fluoro.
  • R 14 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 14 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and Ci_3 alkoxy substituted with C 1 .3 alkoxy.
  • R 14 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • Cy 2 is cycloalkyl optionally substituted with one or more R 16 , phenyl optionally substituted with one or more R 17 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 18 and optionally substituted on an available nitrogen atom with R 19 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, and heteroaryl is pyridinyl or pyrazolyl.
  • Cy 2 is cycloalkyl optionally substituted with one or more R 16 , phenyl optionally substituted with one or more R , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 18 and optionally substituted on an available nitrogen atom with R 19 , wherein cycloalkyl is cyclohexyl, or cycloheptyl, and heteroaryl is pyridin-3-yl or pyrazol-4-yl.
  • L 2 is -C(H 2 )-. In some embodiments of compounds of Formula la, further to any of the above embodiments of Formula la, L 2 is -C(O)-.
  • Cy 3 is cycloalkyl optionally substituted with one or more R 27 , phenyl optionally substituted with one or more R 28 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 29 and optionally substituted on an available nitrogen atom with R 30 ;
  • R 26 is selected from the group consisting of cycloalkyl, lower alkyl optionally substituted with one or more R 31 , and -O-R 32 ;
  • each R 27 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • each R is independently selected from the group consisting of fluoro, chloro, -O-R , -S-R , -S(0 2 )-R 35 , and lower alkyl optionally substitituted with one or more R 36 ;
  • each R 29 is independently selected from the group consisting of fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro; or two R 29 bound to adjacent carbon atoms of the heteroaryl ring, taken together, form a fused cycloalkyl ring;
  • R 30 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • R 31 is fluoro or lower alkoxy optionally substitituted with one or more fluoro; R is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy;
  • each R , ⁇ and R" are independently lower alkyl optionally substituted with one or more
  • each R 36 is independently selected from the group consisting of fluoro, -OH, and lower alkoxy optionally substituted with one or more fluoro.
  • R 26 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 26 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and Ci_3 alkoxy substituted with C 1 .3 alkoxy.
  • R 26 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • Cy 3 is cycloalkyl optionally substituted with one or more R 27 , phenyl optionally substituted with one or more R 28 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 29 and optionally substituted on an available nitrogen atom with R 30 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, and heteroaryl is pyridinyl or pyrazolyl.
  • Cy 3 is cycloalkyl optionally substituted with one or more R 27 , phenyl optionally substituted with one or more R 28 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 29 and optionally substituted on an available nitrogen atom with R 30 , wherein cycloalkyl is cyclohexyl, or cycloheptyl, and heteroaryl is pyridin-3-yl or pyrazol-4-yl.
  • Cy 4 is cycloalkyl optionally substituted with one or more R 38 , phenyl optionally substituted with one or more R 39 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 40 and optionally substituted on an available nitrogen atom with R 41 ;
  • R is selected from the group consisting of cycloalkyl, lower alkyl optionally substituted with one or more R 42 , and -O-R 43 ;
  • each R 38 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • each R 39 is independently selected from the group consisting of fluoro, chloro, -O-R 44 , -S-R 45 , -S(0 2 )-R 46 , and lower alkyl optionally substitituted with one or more R 47 ;
  • each R 40 is independently selected from the group consisting of fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro; or two R 40 bound to adjacent carbon atoms of the heteroaryl ring, taken together, form a fused cycloalkyl ring;
  • R 41 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • R 42 is fluoro or lower alkoxy optionally substitituted with one or more fluoro;
  • R 43 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy;
  • each R 44 , R 45 and R 46 are independently lower alkyl optionally substituted with one or more
  • each R 47 is independently selected from the group consisting of fluoro, -OH, and lower alkoxy optionally substituted with one or more fluoro.
  • R 37 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy. In one embodiment, R 37 is selected from the group consisting of C 3 _ 6 cycloalkyl, Ci_ 3 alkyl, Ci_ 3 alkoxy, and Ci_3 alkoxy substituted with Ci_ 3 alkoxy. In one embodiment, R 37 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • Cy 4 is cycloalkyl optionally substituted with one or more R 38 , phenyl optionally substituted with one or more R 39 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 40 and optionally substituted on an available nitrogen atom with R 41 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, and heteroaryl is pyridinyl or pyrazolyl.
  • Cy 4 is cycloalkyl optionally substituted with one or more R 38 , phenyl optionally substituted with one or more R 39 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 40 and optionally substituted on an available nitrogen atom with R 41 , wherein cycloalkyl is cyclohexyl, or cycloheptyl, and heteroaryl is pyridin-3-yl or pyrazol-4-yl.
  • Cy 5 is cycloalkyl optionally substituted with one or more R 49 , phenyl optionally substituted with one or more R 50 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 51 and optionally substituted on an available nitrogen atom with R 52 ;
  • R 48 is selected from the group consisting of cycloalkyl, lower alkyl optionally substituted with one or more R 53 , and -O-R 54 ;
  • each R 49 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • each R 50 is independently selected from the group consisting of fluoro, chloro, -O-R 55 , -S-R 56 , -S(0 2 )-R 57 , and lower alkyl optionally substitituted with one or more R 58 ;
  • each R 51 is independently selected from the group consisting of fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro; or two R 51 bound to adjacent carbon atoms of the heteroaryl ring, taken together, form a fused cycloalkyl ring;
  • R 52 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • R 53 is fluoro or lower alkoxy optionally substitituted with one or more fluoro;
  • R 54 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy;
  • each R 55 , R 56 and R 57 are independently lower alkyl optionally substituted with one or more
  • each R 58 is independently selected from the group consisting of fluoro, -OH, and lower alkoxy optionally substituted with one or more fluoro.
  • R 48 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 48 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and Ci_3 alkoxy substituted with C 1 .3 alkoxy.
  • R 48 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • Cy 5 is cycloalkyl optionally substituted with one or more R 49 , phenyl optionally substituted with one or more R 50 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 51 and optionally substituted on an available nitrogen atom with R 52 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, and heteroaryl is pyridinyl or pyrazolyl.
  • Cy 5 is cycloalkyl optionally substituted with one or more R 49 , phenyl optionally substituted with one or more R 50 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 51 and optionally substituted on an available nitrogen atom with R 52 , wherein cycloalkyl is cyclohexyl, or cycloheptyl, and heteroaryl is pyridin-3-yl or pyrazol-4-yl.
  • Cy 6 is cycloalkyl optionally substituted with one or more R 60 , phenyl optionally substituted with one or more R 61 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 62 and optionally substituted on an available nitrogen atom with R 63 ;
  • R 59 is selected from the group consisting of cycloalkyl, lower alkyl optionally substituted with one or more R 64 , and -O-R 65 ;
  • each R 60 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • each R 61 is independently selected from the group consisting of fluoro, chloro, -O-R 66 , -S-R 67 , -S(0 2 )-R 68 , and lower alkyl optionally substitituted with one or more R 69 ;
  • each R 62 is independently selected from the group consisting of fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro; or two R 62 bound to adjacent carbon atoms of the heteroaryl ring, taken together, form a fused cycloalkyl ring;
  • R 63 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro; R is fluoro or lower alkoxy optionally substitituted with one or more fluoro;
  • R 65 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy;
  • each R 66 , R 67 and R 68 are independently lower alkyl optionally substituted with one or more
  • each R 69 is independently selected from the group consisting of fluoro, -OH, and lower alkoxy optionally substituted with one or more fluoro.
  • R 59 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 59 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and Ci_3 alkoxy substituted with C 1 .3 alkoxy.
  • R 59 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • ye is cycloalkyl optionally substituted with one or more R 60 , phenyl optionally substituted with one or more R 61 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 62 and optionally substituted on an available nitrogen atom with R 63 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, and heteroaryl is pyridinyl or pyrazolyl.
  • Cy 6 is cycloalkyl optionally substituted with one or more R 60 , phenyl optionally substituted with one or more R 61 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 62 and optionally substituted on an available nitrogen atom with R 63 , wherein cycloalkyl is cyclohexyl, or cycloheptyl, and heteroaryl is pyridin-3-yl or pyrazol-4-yl.
  • L 3 is -C(H 2 )- or -C(O)-;
  • Cy 7 is cycloalkyl optionally substituted with one or more R , phenyl optionally substituted with one or more R 73 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 74 and optionally substituted on an available nitrogen atom with R 75 ;
  • R 70 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro; each R 72 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • each R 73 is independently selected from the group consisting of fluoro, chloro, -O-R 76 , -S-R 77 , -S(0 2 )-R 78 , and lower alkyl optionally substitituted with one or more R 79 ;
  • each R 74 is independently selected from the group consisting of fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro; or two R 74 bound to adjacent carbon atoms of the heteroaryl ring, taken together, form a fused cycloalkyl ring;
  • R 75 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • each R 76 , R 77 and R 78 are independently lower alkyl optionally substituted with one or more
  • each R 79 is independently selected from the group consisting of fluoro, -OH, and lower alkoxy optionally substituted with one or more fluoro.
  • R 70 is hydrogen, chloro or lower alkyl. In one embodiment, R 70 is hydrogen, chloro or Ci_ 3 alkyl. In one embodiment, R 70 is hydrogen, chloro or methyl.
  • Cy 7 is cycloalkyl optionally substituted with one or more R 72 , phenyl optionally substituted with one or more R 73 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 74 and optionally substituted on an available nitrogen atom with R 75 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, and heteroaryl is pyridinyl or pyrazolyl.
  • Cy 7 is cycloalkyl optionally substituted with one or more R 72 , phenyl optionally substituted with one or more R 73 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 74 and optionally substituted on an available nitrogen atom with R 75 , wherein cycloalkyl is cyclohexyl, or cycloheptyl, and heteroaryl is pyridin-3-yl or pyrazol-4-yl.
  • L 3 is -C(H 2 )-. In some embodiments of compounds of Formula If, further to any of the above embodiments of Formula If, L 3 is -C(O)-.
  • Cyg is cycloalkyl optionally substituted with one or more R 81 , phenyl optionally substituted with one or more R 82 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 83 and optionally substituted on an available nitrogen atom with R 84 ;
  • R 80 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro; each R 81 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • each R 82 is independently selected from the group consisting of fluoro, chloro, -O-R 85 , -S-R 86 , -S(0 2 )-R 87 , and lower alkyl optionally substitituted with one or more R 88 ;
  • each R 83 is independently selected from the group consisting of fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro; or two R 83 bound to adjacent carbon atoms of the heteroaryl ring, taken together, form a fused cycloalkyl ring;
  • R 84 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • each R 85 , R 86 and R 87 are independently lower alkyl optionally substituted with one or more
  • each R 88 is independently selected from the group consisting of fluoro, -OH, and lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen, chloro or lower alkyl.
  • R 80 is hydrogen, chloro or Ci_ 3 alkyl.
  • R 80 is hydrogen, chloro or methyl.
  • Cy 8 is cycloalkyl optionally substituted with one or more R 81 , phenyl optionally substituted with one or more R 82 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 83 and optionally substituted on an available nitrogen atom with R 84 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, and heteroaryl is pyridinyl or pyrazolyl.
  • Cyg is cycloalkyl optionally substituted with one or more R 81 , phenyl optionally substituted with one or more R 82 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 83 and optionally substituted on an available nitrogen atom with R 84 , wherein cycloalkyl is cyclohexyl, or cycloheptyl, and heteroaryl is pyridin-3-yl or pyrazol-4-yl.
  • Cy 9 is cycloalkyl optionally substituted with one or more R 90 , phenyl optionally substituted with one or more R 91 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 92 and optionally substituted on an available nitrogen atom with R 93 ;
  • R 89 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro; each R 90 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • each R 91 is independently selected from the group consisting of fluoro, chloro, -O-R 94 , -S-R 95 , -S(0 2 )-R 96 , and lower alkyl optionally substitituted with one or more R 97 ;
  • each R 92 is independently selected from the group consisting of fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro; or two R bound to adjacent carbon atoms of the heteroaryl ring, taken together, form a fused cycloalkyl ring;
  • R 93 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • each R 94 , R 95 and R 96 are independently lower alkyl optionally substituted with one or more
  • each R 97 is independently selected from the group consisting of fluoro, -OH, and lower alkoxy optionally substituted with one or more fluoro.
  • R 89 is hydrogen, chloro or lower alkyl. In one embodiment, R 89 is hydrogen, chloro or C 1 .3 alkyl. In one embodiment, R 89 is hydrogen, chloro or methyl.
  • Cyg is cycloalkyl optionally substituted with one or more R 90 , phenyl optionally substituted with one or more R 91 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 92 and optionally substituted on an available nitrogen atom with R 93 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, and heteroaryl is pyridinyl or pyrazolyl.
  • Cy 9 is cycloalkyl optionally substituted with one or more R 90 , phenyl optionally substituted with one or more R 91 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 92 and optionally substituted on an available nitrogen atom with R 93 , wherein cycloalkyl is cyclohexyl, or cycloheptyl, and heteroaryl is pyridin-3-yl or pyrazol-4-yl.
  • Cyio is cycloalkyl optionally substituted with one or more R 99 , phenyl optionally substituted with one or more R 100 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 101 and optionally substituted on an available nitrogen atom with
  • R is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro; each R 99 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • each R 100 is independently selected from the group consisting of fluoro, chloro, -O-R 103 , -S-R 104 , -S(0 2 )-R 105 , and lower alkyl optionally substitituted with one or more R 106 ;
  • each R 101 is independently selected from the group consisting of fluoro, chloro, bromo,
  • cycloalkyl lower alkyl optionally substituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro; or two R 101 bound to adjacent carbon atoms of the heteroaryl ring, taken together, form a fused cycloalkyl ring;
  • R 102 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • each R 102 , R 104 and R 105 are independently lower alkyl optionally substituted with one or more fluoro;
  • each R 106 is independently selected from the group consisting of fluoro, -OH, and lower alkoxy optionally substituted with one or more fluoro.
  • R 98 is hydrogen, chloro or lower alkyl. In one embodiment, R 98 is hydrogen, chloro or Ci_ 3 alkyl. In one embodiment, R 98 is hydrogen, chloro or methyl.
  • Cyio is cycloalkyl optionally substituted with one or more R 99 , phenyl optionally substituted with one or more R 100 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 101 and optionally substituted on an available nitrogen atom with R 102 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, and heteroaryl is pyridinyl or pyrazolyl.
  • Cyio is cycloalkyl optionally substituted with one or more R 99 , phenyl optionally substituted with one or more R 100 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 101 and optionally substituted on an available nitrogen atom with R 102 , wherein cycloalkyl is cyclohexyl, or cycloheptyl, and heteroaryl is pyridin-3-yl or pyrazol- 4-yl.
  • Cyn is cycloalkyl optionally substituted with one or more R 108 , phenyl optionally substituted with one or more R 109 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 110 and optionally substituted on an available nitrogen atom with
  • R is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro; each R 108 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • each R 109 is independently selected from the group consisting of fluoro, chloro, -O-R 112 , -S-R 113 , -S(0 2 )-R 114 , and lower alkyl optionally substitituted with one or more R 115 ;
  • each R 110 is independently selected from the group consisting of fluoro, chloro, bromo,
  • cycloalkyl lower alkyl optionally substituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro; or two R 110 bound to adjacent carbon atoms of the heteroaryl ring, taken together, form a fused cycloalkyl ring;
  • R 111 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • each R 112 , R 113 and R 114 are independently lower alkyl optionally substituted with one or more fluoro;
  • each R 115 is independently selected from the group consisting of fluoro, -OH, and lower alkoxy optionally substituted with one or more fluoro.
  • R 107 is hydrogen, chloro or lower alkyl.
  • R 107 is hydrogen, chloro or Ci_ 3 alkyl. In one embodiment, R 107 is hydrogen, chloro or methyl.
  • Cyn is cycloalkyl optionally substituted with one or more R 108 , phenyl optionally substituted with one or more R 109 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 110 and optionally substituted on an available nitrogen atom with R 111 , wherein cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, and heteroaryl is pyridinyl or pyrazolyl.
  • Cyn is cycloalkyl optionally substituted with one or more R 108 , phenyl optionally substituted with one or more R 109 , or 5 or 6 membered heteroaryl optionally substituted on an available carbon atom with one or more R 110 and optionally substituted on an available nitrogen atom with R 111 , wherein cycloalkyl is cyclohexyl, or cycloheptyl, and heteroaryl is pyridin-3-yl or pyrazol- 4-yl.
  • L 4 is -C(H 2 )- or -C(O)-;
  • Cy i2 is cycloalkyl optionally substituted with one or more R 119 ;
  • R 117 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally substituted with one or more R 120 , and -O-R 121 ;
  • R 116 is fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • each R 119 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • R 120 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 121 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • Cyi 2 is cyclopentyl optionally substituted with 1 or 2 R 119 , cyclohexyl optionally substituted with 1 or 2 R 119 , or cycloheptyl optionally substituted with 1 or 2 R 119 .
  • Cyi 2 is cyclopentyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; cyclohexyl optionally substituted with 1 or 2 fluoro, or lor 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; or cycloheptyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy.
  • Cy i2 is cyclopentyl, cyclopentyl substituted with 1 or 2 fluoro, cyclopentyl substituted with 1 or 2 lower alkyl, cyclopentyl substituted with 1 or 2 -OH, or cyclopentyl substituted with 1 or 2 lower alkoxy.
  • Cy i2 is cyclohexyl, cyclohexyl substituted with 1 or 2 fluoro, cyclohexyl substituted with 1 or 2 lower alkyl, cyclohexyl substituted with 1 or 2 -OH, or cyclohexyl substituted with 1 or 2 lower alkoxy.
  • Cyi 2 is cycloheptyl, cycloheptyl substituted with 1 or 2 fluoro, cycloheptyl substituted with 1 or 2 lower alkyl, cycloheptyl substituted with 1 or 2 -OH, or cycloheptyl substituted with 1 or 2 lower alkoxy.
  • L 5 is -C(H 2 )- or -C(O)-;
  • Cy i3 is cycloalkyl optionally substituted with one or more R 124 ;
  • R 122 is selected from the group consisting of cycloalkyl, lower alkyl optionally substituted with one or more R 125 , and -O-R 126 ;
  • each R 124 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • R 125 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 126 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 122 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 122 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and C 1 .3 alkoxy substituted with C 1 .3 alkoxy.
  • R 122 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • Cy i3 is cyclopentyl optionally substituted with 1 or 2 R 124 , cyclohexyl
  • Cy i3 is cyclopentyl optionally substituted with 1 or 2 fluoro, or l or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; cyclohexyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; or cycloheptyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy.
  • Cy i3 is cyclopentyl, cyclopentyl substituted with 1 or 2 fluoro, cyclopentyl substituted with 1 or 2 lower alkyl, cyclopentyl substituted with 1 or 2 -OH, or cyclopentyl substituted with 1 or 2 lower alkoxy.
  • Cyo is cyclohexyl, cyclohexyl substituted with 1 or 2 fluoro, cyclohexyl substituted with 1 or 2 lower alkyl, cyclohexyl substituted with 1 or 2 -OH, or cyclohexyl substituted with 1 or 2 lower alkoxy.
  • Cyo is cycloheptyl, cycloheptyl substituted with 1 or 2 fluoro, cycloheptyl substituted with 1 or 2 lower alkyl, cycloheptyl substituted with 1 or 2 -OH, or cycloheptyl substituted with 1 or 2 lower alkoxy.
  • L 5 is -C(H 2 )-. In some embodiments of compounds of Formula Im, further to any of the above embodiments of Formula Im, L 5 is -C(O)-.
  • Cy i4 is cycloalkyl optionally substituted with one or more R 128 ;
  • R 127 is selected from the group consisting of cycloalkyl, lower alkyl optionally substituted with one or more R 129 , and -O-R 130 ; each R is independently selected from the group consisting of fluoro, -OH, lower alkyl optionally substitituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro;
  • R 129 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 130 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 127 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 127 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and C 1 .3 alkoxy substituted with C 1 .3 alkoxy.
  • R 127 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • Cyi 4 is cyclopentyl optionally substituted with 1 or 2 R 128 , cyclohexyl optionally
  • Cy i4 is cyclopentyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; cyclohexyl optionally substituted with 1 or 2 fluoro, or l or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; or cycloheptyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy.
  • Cy i4 is cyclopentyl, cyclopentyl substituted with 1 or 2 fluoro, cyclopentyl substituted with 1 or 2 lower alkyl, cyclopentyl substituted with 1 or 2 -OH, or cyclopentyl substituted with 1 or 2 lower alkoxy.
  • Cyi 4 is cyclohexyl, cyclohexyl substituted with 1 or 2 fluoro, cyclohexyl substituted with 1 or 2 lower alkyl, cyclohexyl substituted with 1 or 2 -OH, or cyclohexyl substituted with 1 or 2 lower alkoxy.
  • Cyi 4 is cycloheptyl, cycloheptyl substituted with 1 or 2 fluoro, cycloheptyl substituted with 1 or 2 lower alkyl, cycloheptyl substituted with 1 or 2 -OH, or cycloheptyl substituted with 1 or 2 lower alkoxy.
  • compounds of Formula I having the structure according to the following Formula Io are provided:
  • Cy i5 is cycloalkyl optionally substituted with one or more R 132 ;
  • R 131 is selected from the group consisting of cycloalkyl, lower alkyl optionally substituted with one or more R 133 , and -O-R 134 ;
  • each R 132 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • R 133 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 134 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 131 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 131 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and C 1 .3 alkoxy substituted with C 1 .3 alkoxy.
  • R 131 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • Cyi 5 is cyclopentyl optionally substituted with 1 or 2 R 132 , cyclohexyl optionally
  • Cy i5 is cyclopentyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; cyclohexyl optionally substituted with 1 or 2 fluoro, or l or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; or cycloheptyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy.
  • Cy i5 is cyclopentyl, cyclopentyl substituted with 1 or 2 fluoro, cyclopentyl substituted with 1 or 2 lower alkyl, cyclopentyl substituted with 1 or 2 -OH, or cyclopentyl substituted with 1 or 2 lower alkoxy.
  • Cy i5 is cyclohexyl, cyclohexyl substituted with 1 or 2 fluoro, cyclohexyl substituted with 1 or 2 lower alkyl, cyclohexyl substituted with 1 or 2 -OH, or cyclohexyl substituted with 1 or 2 lower alkoxy.
  • Cyi 5 is cycloheptyl, cycloheptyl substituted with 1 or 2 fluoro, cycloheptyl substituted with 1 or 2 lower alkyl, cycloheptyl substituted with 1 or 2 -OH, or cycloheptyl substituted with 1 or 2 lower alkoxy.
  • Cy i6 is cycloalkyl optionally substituted with one or more R 136 ;
  • R 135 is selected from the group consisting of cycloalkyl, lower alkyl optionally substituted with one or more R 137 , and -O-R 138 ;
  • each R 136 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • R 137 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 138 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 135 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 135 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and Ci_ 3 alkoxy substituted with Ci_ 3 alkoxy.
  • R 135 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • Cy i6 is cyclopentyl optionally substituted with 1 or 2 R 136 , cyclohexyl optionally substituted with 1 or 2 R 136 , or cycloheptyl optionally substituted with 1 or 2 R 136 .
  • Cy i6 is cyclopentyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; cyclohexyl optionally substituted with 1 or 2 fluoro, or lor 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; or cycloheptyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy.
  • Cyi 6 is cyclopentyl, cyclopentyl substituted with 1 or 2 fluoro, cyclopentyl substituted with 1 or 2 lower alkyl, cyclopentyl substituted with 1 or 2 -OH, or cyclopentyl substituted with 1 or 2 lower alkoxy.
  • Cyi 6 is cyclohexyl, cyclohexyl substituted with 1 or 2 fluoro, cyclohexyl substituted with 1 or 2 lower alkyl, cyclohexyl substituted with 1 or 2 -OH, or cyclohexyl substituted with 1 or 2 lower alkoxy.
  • Cy i6 is cycloheptyl, cycloheptyl substituted with 1 or 2 fluoro, cycloheptyl substituted with 1 or 2 lower alkyl, cycloheptyl substituted with 1 or 2 -OH, or cycloheptyl substituted with 1 or 2 lower alkoxy.
  • Cy i6 is cycloalkyl optionally substituted with one or more R 140 ;
  • R 139 is selected from the group consisting of cycloalkyl, lower alkyl optionally substituted with one or more R 141 , and -O-R 142 ; each R is independently selected from the group consisting of fluoro, -OH, lower alkyl optionally substitituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro;
  • R 141 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 142 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 139 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 139 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and C 1 .3 alkoxy substituted with C 1 .3 alkoxy.
  • R 139 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • Cyn is cyclopentyl optionally substituted with 1 or 2 R 140 , cyclohexyl optionally substituted with 1 or 2 R 140 , or cycloheptyl optionally substituted with 1 or 2 R 140 .
  • Cyn is cyclopentyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; cyclohexyl optionally substituted with 1 or 2 fluoro, or l or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; or cycloheptyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy.
  • Cyn is cyclopentyl, cyclopentyl substituted with 1 or 2 fluoro, cyclopentyl substituted with 1 or 2 lower alkyl, cyclopentyl substituted with 1 or 2 -OH, or cyclopentyl substituted with 1 or 2 lower alkoxy.
  • Cyn is cyclohexyl, cyclohexyl substituted with 1 or 2 fluoro, cyclohexyl substituted with 1 or 2 lower alkyl, cyclohexyl substituted with 1 or 2 -OH, or cyclohexyl substituted with 1 or 2 lower alkoxy.
  • Cyn is cycloheptyl, cycloheptyl substituted with 1 or 2 fluoro, cycloheptyl substituted with 1 or 2 lower alkyl, cycloheptyl substituted with 1 or 2 -OH, or cycloheptyl substituted with 1 or 2 lower alkoxy.
  • compounds of Formula I having the structure according to the following Formula Ir are provide
  • L 6 is -C(H 2 )- or -C(0)-;
  • Cyig is cycloalkyl optionally substituted with one or more R 145 ;
  • R 143 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • each R 145 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • R 143 is hydrogen, chloro or lower alkyl. In one embodiment, R 143 is hydrogen, chloro or Ci_ 3 alkyl. In one embodiment, R 143 is hydrogen, chloro or methyl.
  • Cy i8 is cyclopentyl optionally substituted with 1 or 2 R 145 , cyclohexyl optionally substituted with 1 or 2 R 145 , or cycloheptyl optionally substituted with 1 or 2 R 145 .
  • Cyig is cyclopentyl optionally substituted with 1 or 2 fluoro, or lor 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; cyclohexyl optionally substituted with 1 or 2 fluoro, or lor 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; or cycloheptyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy.
  • Cyig is cyclopentyl, cyclopentyl substituted with 1 or 2 fluoro, cyclopentyl substituted with 1 or 2 lower alkyl, cyclopentyl substituted with 1 or 2 -OH, or cyclopentyl substituted with 1 or 2 lower alkoxy.
  • Cyi 8 is cyclohexyl, cyclohexyl substituted with 1 or 2 fluoro, cyclohexyl substituted with 1 or 2 lower alkyl, cyclohexyl substituted with 1 or 2 -OH, or cyclohexyl substituted with 1 or 2 lower alkoxy.
  • Cyig is cycloheptyl, cycloheptyl substituted with 1 or 2 fluoro, cycloheptyl substituted with 1 or 2 lower alkyl, cycloheptyl substituted with 1 or 2 -OH, or cycloheptyl substituted with 1 or 2 lower alkoxy.
  • L 6 is -C(H 2 )-. In some embodiments of compounds of Formula Ir, further to any of the above embodiments of Formula Ir, L 6 is -C(O)-.
  • Cy i9 is cycloalkyl optionally substituted with one or more R 147 ;
  • R 146 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • each R 147 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • R 146 is hydrogen, chloro or lower alkyl. In one embodiment, R 146 is hydrogen, chloro or C 1 .3 alkyl. In one embodiment, R 146 is hydrogen, chloro or methyl. [0122] In some embodiments of compounds of Formula Is, further to any of the above embodiments of Formula Is, Cy i9 is cyclopentyl optionally substituted with 1 or 2 R 147 , cyclohexyl optionally substituted with 1 or 2 R 147 , or cycloheptyl optionally substituted with 1 or 2 R 147 .
  • Cy i9 is cyclopentyl optionally substituted with 1 or 2 fluoro, or lor 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; cyclohexyl optionally substituted with 1 or 2 fluoro, or lor 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; or cycloheptyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy.
  • Cyig is cyclopentyl, cyclopentyl substituted with 1 or 2 fluoro, cyclopentyl substituted with 1 or 2 lower alkyl, cyclopentyl substituted with 1 or 2 -OH, or cyclopentyl substituted with 1 or 2 lower alkoxy.
  • Cyig is cyclohexyl, cyclohexyl substituted with 1 or 2 fluoro, cyclohexyl substituted with 1 or 2 lower alkyl, cyclohexyl substituted with 1 or 2 -OH, or cyclohexyl substituted with 1 or 2 lower alkoxy.
  • Cy i9 is cycloheptyl, cycloheptyl substituted with 1 or 2 fluoro, cycloheptyl substituted with 1 or 2 lower alkyl, cycloheptyl substituted with 1 or 2 -OH, or cycloheptyl substituted with 1 or 2 lower alkoxy.
  • Cy 2 o is cycloalkyl optionally substituted with one or more R 149 ;
  • R 148 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro; and each R is independently selected from the group consisting of fluoro, -OH, lower alkyl optionally substitituted with one or more fluoro, and lower alkoxy optionally substituted with one or more fluoro.
  • R 148 is hydrogen, chloro or lower alkyl. In one embodiment, R 148 is hydrogen, chloro or Ci_ 3 alkyl. In one embodiment, R 148 is hydrogen, chloro or methyl.
  • Cy 2 o is cyclopentyl optionally substituted with 1 or 2 R 149 , cyclohexyl optionally substituted with 1 or 2 R 149 , or cycloheptyl optionally substituted with 1 or 2 R 149 .
  • Cy 2 o is cyclopentyl optionally substituted with 1 or 2 fluoro, or lor 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; cyclohexyl optionally substituted with 1 or 2 fluoro, or lor 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; or cycloheptyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy.
  • Cy 2 o is cyclopentyl, cyclopentyl substituted with 1 or 2 fluoro, cyclopentyl substituted with 1 or 2 lower alkyl, cyclopentyl substituted with 1 or 2 -OH, or cyclopentyl substituted with 1 or 2 lower alkoxy.
  • Cy 2 o is cyclohexyl, cyclohexyl substituted with 1 or 2 fluoro, cyclohexyl substituted with 1 or 2 lower alkyl, cyclohexyl substituted with 1 or 2 -OH, or cyclohexyl substituted with 1 or 2 lower alkoxy.
  • Cy 2 o is cycloheptyl, cycloheptyl substituted with 1 or 2 fluoro, cycloheptyl substituted with 1 or 2 lower alkyl, cycloheptyl substituted with 1 or 2 -OH, or cycloheptyl substituted with 1 or 2 lower alkoxy.
  • Cy 2 i is cycloalkyl optionally substituted with one or more R 151 ;
  • R 150 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • each R 151 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • R 150 is hydrogen, chloro or lower alkyl. In one embodiment, R 150 is hydrogen, chloro or C 1 .3 alkyl. In one embodiment, R 150 is hydrogen, chloro or methyl.
  • Cy 2 i is cyclopentyl optionally substituted with 1 or 2 R 151 , cyclohexyl optionally substituted with 1 or 2 R 151 , or cycloheptyl optionally substituted with 1 or 2 R 151 .
  • Cy 2 i is cyclopentyl optionally substituted with 1 or 2 fluoro, or l or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; cyclohexyl optionally substituted with 1 or 2 fluoro, or l or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; or cycloheptyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy.
  • Cy 2 i is cyclopentyl, cyclopentyl substituted with 1 or 2 fluoro, cyclopentyl substituted with 1 or 2 lower alkyl, cyclopentyl substituted with 1 or 2 -OH, or cyclopentyl substituted with 1 or 2 lower alkoxy.
  • Cy 2 i is cyclohexyl, cyclohexyl substituted with 1 or 2 fluoro, cyclohexyl substituted with 1 or 2 lower alkyl, cyclohexyl substituted with 1 or 2 -OH, or cyclohexyl substituted with 1 or 2 lower alkoxy.
  • Cy 2 i is cycloheptyl, cycloheptyl substituted with 1 or 2 fluoro, cycloheptyl substituted with 1 or 2 lower alkyl, cycloheptyl substituted with 1 or 2 -OH, or cycloheptyl substituted with 1 or 2 lower alkoxy.
  • Cy 22 is cycloalkyl optionally substituted with one or more R 153 ;
  • R 152 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • each R 153 is independently selected from the group consisting of fluoro, -OH, lower alkyl
  • R 152 is hydrogen, chloro or lower alkyl. In one embodiment, R 152 is hydrogen, chloro or C 1 .3 alkyl. In one embodiment, R 152 is hydrogen, chloro or methyl.
  • Cy 22 is cyclopentyl optionally substituted with 1 or 2 R 153 , cyclohexyl optionally substituted with 1 or 2 R 153 , or cycloheptyl optionally substituted with 1 or 2 R 153 .
  • Cy 22 is cyclopentyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; cyclohexyl optionally substituted with 1 or 2 fluoro, or l or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy; or cycloheptyl optionally substituted with 1 or 2 fluoro, or 1 or 2 lower alkyl, or 1 or 2 -OH, or 1 or 2 lower alkoxy.
  • Cy 22 is cyclopentyl, cyclopentyl substituted with 1 or 2 fluoro, cyclopentyl substituted with 1 or 2 lower alkyl, cyclopentyl substituted with 1 or 2 -OH, or cyclopentyl substituted with 1 or 2 lower alkoxy.
  • Cy 22 is cyclohexyl, cyclohexyl substituted with 1 or 2 fluoro, cyclohexyl substituted with 1 or 2 lower alkyl, cyclohexyl substituted with 1 or 2 -OH, or cyclohexyl substituted with 1 or 2 lower alkoxy.
  • Cy 2 2 is cycloheptyl, cycloheptyl substituted with 1 or 2 fluoro, cycloheptyl substituted with 1 or 2 lower alkyl, cycloheptyl substituted with 1 or 2 -OH, or cycloheptyl substituted with 1 or 2 lower alkoxy.
  • L 7 is -C(H 2 )- or -C(O)-;
  • R 155 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally substituted with one or more R 158 , and -O-R 159 ;
  • R 154 is fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • R 157 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • R 158 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 159 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 155 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 155 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • R 157 is cycloalkyl or lower alkyl.
  • R 157 is C 3 _6 cycloalkyl or lower alkyl.
  • R 157 is cyclopropyl or lower alkyl.
  • R 157 is lower alkyl.
  • R 157 is Q_ 3 alkyl.
  • R 157 is ethyl
  • L 7 is -C(H 2 )-. In some embodiments of compounds of Formula Iw, further to any of the above embodiments of Formula Iw, L 7 is -C(O)-.
  • L 8 is -C(H 2 )- or -C(0)-;
  • R 160 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally
  • R 162 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • R 163 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 164 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 160 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 160 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and C 1 .3 alkoxy substituted with C 1 .3 alkoxy.
  • R 160 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • R 162 is cycloalkyl or lower alkyl.
  • R 162 is C 3 . 6 cycloalkyl or lower alkyl.
  • R 162 is cyclopropyl or lower alkyl.
  • R 162 is lower alkyl
  • R 162 is C 1 .3 alkyl.
  • R 162 is ethyl
  • R 165 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally
  • R 166 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • R 167 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 168 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 165 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 165 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and Ci_ 3 alkoxy substituted with Ci_ 3 alkoxy.
  • R 165 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • R 166 is cycloalkyl or lower alkyl.
  • R 166 is C3.6 cycloalkyl or lower alkyl.
  • R 166 is cyclopropyl or lower alkyl.
  • R 166 is lower alkyl.
  • R 166 is Ci_ 3 alkyl.
  • R 166 is ethyl
  • R 169 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally
  • R 170 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • R 171 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 172 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 169 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy. In one embodiment, R 169 is selected from the group consisting of C3.6 cycloalkyl, C1.3 alkyl, C1.3 alkoxy, and C1.3 alkoxy substituted with C1.3 alkoxy. In one embodiment, R 169 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • R 170 is cycloalkyl or lower alkyl.
  • R 170 is C3.6 cycloalkyl or lower alkyl.
  • R 170 is cyclopropyl or lower alkyl.
  • R 170 is lower alkyl.
  • R 170 is Ci_ 3 alkyl.
  • R 170 is ethyl
  • R 173 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally
  • R 174 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • R 175 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 176 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 173 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 173 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and Ci_ 3 alkoxy substituted with Ci_ 3 alkoxy.
  • R 173 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • R 174 is cycloalkyl or lower alkyl.
  • R 174 is C3.6 cycloalkyl or lower alkyl.
  • R 174 is cyclopropyl or lower alkyl.
  • R 174 is lower alkyl. [0191] In some embodiments of compounds of Formula Iaa, further to any of the above embodiments of Formula Iaa, R 174 is Ci_ 3 alkyl.
  • R 174 is ethyl
  • R 177 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally
  • R 178 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro;
  • R 179 is fluoro or lower alkoxy optionally substitituted with one or more fluoro
  • R 180 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 177 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 177 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and Ci_ 3 alkoxy substituted with Ci_ 3 alkoxy.
  • R 177 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • R 178 is cycloalkyl or lower alkyl.
  • R 178 is C3.6 cycloalkyl or lower alkyl.
  • R 178 is cyclopropyl or lower alkyl.
  • R 178 is lower alkyl.
  • R 178 is Ci_ 3 alkyl.
  • R 178 is ethyl
  • L 9 is -C(H 2 )- or -C(O)-;
  • R 181 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • R 183 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 181 is hydrogen, chloro or lower alkyl. In one embodiment, R 181 is hydrogen, chloro or C 1 .3 alkyl. In one embodiment, R 181 is hydrogen, chloro or methyl.
  • R 183 is cycloalkyl or lower alkyl.
  • R 183 is C3.6 cycloalkyl or lower alkyl.
  • R 183 is cyclopropyl or lower alkyl.
  • R 183 is lower alkyl.
  • R 183 is Ci_ 3 alkyl.
  • R 183 is ethyl
  • L 9 is -C(H 2 )-. In some embodiments of compounds of Formula Icc, further to any of the above embodiments of Formula Icc, L 9 is -C(O)-.
  • R 182 is fluoro.
  • R 184 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • R 185 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 184 is hydrogen, chloro or lower alkyl. In one embodiment, R 184 is hydrogen, chloro or Ci_ 3 alkyl. In one embodiment, R 184 is hydrogen, chloro or methyl.
  • R 185 is cycloalkyl or lower alkyl.
  • R 185 is C 3 . 6 cycloalkyl or lower alkyl.
  • R 185 is cyclopropyl or lower alkyl. [0216] In some embodiments of compounds of Formula Idd, further to any of the above embodiments of Formula Idd, R 185 is lower alkyl.
  • R 185 is Ci_ 3 alkyl.
  • R 185 is ethyl
  • R 186 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • R 187 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 186 is hydrogen, chloro or lower alkyl. In one embodiment, R 186 is hydrogen, chloro or C 1 .3 alkyl. In one embodiment, R 186 is hydrogen, chloro or methyl.
  • R 187 is cycloalkyl or lower alkyl.
  • R 187 is C 3 . 6 cycloalkyl or lower alkyl.
  • R 187 is cyclopropyl or lower alkyl.
  • R 187 is lower alkyl.
  • R 187 is C 1 .3 alkyl.
  • R 187 is ethyl.
  • R 188 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • R 189 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 188 is hydrogen, chloro or lower alkyl. In one embodiment, R 188 is hydrogen, chloro or Ci_ 3 alkyl. In one embodiment, R 188 is hydrogen, chloro or methyl.
  • R 189 is cycloalkyl or lower alkyl.
  • R 189 is C 3 . 6 cycloalkyl or lower alkyl.
  • R 189 is cyclopropyl or lower alkyl.
  • R 189 is lower alkyl.
  • R 189 is C 1 .3 alkyl.
  • R 189 is ethyl.
  • R 190 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • R 191 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 190 is hydrogen, chloro or lower alkyl. In one embodiment, R 190 is hydrogen, chloro or Ci_ 3 alkyl. In one embodiment, R 190 is hydrogen, chloro or methyl.
  • R 191 is cycloalkyl or lower alkyl.
  • R 191 is C 3 . 6 cycloalkyl or lower alkyl.
  • R 191 is cyclopropyl or lower alkyl.
  • R 191 is lower alkyl.
  • R 191 is C 1 .3 alkyl.
  • R 191 is ethyl
  • Lio is -C(H 2 )- or -C(O)-;
  • R 193 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally substituted with one or more R 197 , and -O-R 198 ;
  • R 192 is fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • R 195 is hydrogen and R 196 is hydrogen, fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; or
  • R 196 is hydrogen and R 195 is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; R 197 is fluoro or lower alkoxy optionally substitituted with one or more fluoro; and
  • R 198 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 193 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 196 is hydrogen and R 195 is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 196 is hydrogen and R 195 is lower alkyl optionally substituted with one or more fluoro.
  • R 196 is hydrogen and R 195 is lower alkyl.
  • R 196 is hydrogen and R 195 is C 1 .3 alkyl. In some embodiments of compounds of Formula Ihh, further to any of the above embodiments of Formula Ihh, R 196 is hydrogen and R 195 is methyl.
  • R 195 is hydrogen and R 196 is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 195 is hydrogen and R 196 is fluoro, chloro, bromo.
  • R 195 is hydrogen and R 196 is cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 195 is hydrogen and R 196 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 195 is hydrogen and R 196 is cycloalkyl or Ci_ 3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 195 is hydrogen and R 196 is cyclopropyl or Ci_3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 195 is hydrogen and R 196 is cyclopropyl, trifluoromethyl, methyl or ethyl.
  • R 195 is hydrogen and R 196 is cycloalkyl.
  • R 195 is hydrogen and R 196 is cyclopropyl.
  • R 195 is hydrogen and R 196 is lower alkyl optionally substituted with one or more fluoro.
  • R is hydrogen and R is Ci_ 3 alkyl optionally substituted with 1 , 2, or 3 fluoro.
  • R 195 is hydrogen and R 196 is trifluoromethyl, methyl or ethyl.
  • R 195 is hydrogen and R 196 is trifluoromethyl.
  • R 195 is hydrogen and R 196 is methyl. In some embodiments of compounds of Formula Ihh, further to any of the above embodiments of Formula Ihh, R 195 is hydrogen and R 196 is ethyl.
  • R 195 is hydrogen and R 196 is lower alkoxy optionally substituted with one or more fluoro.
  • R 195 is hydrogen and R 196 is lower alkoxy.
  • R 195 is hydrogen and R 196 is C 1 .3 alkoxy.
  • R 195 is hydrogen and R 196 is methoxy or ethoxy.
  • R 195 is hydrogen and R 196 is methoxy. In some embodiments of compounds of Formula Ihh, further to any of the above embodiments of Formula Ihh, R 195 is hydrogen and R 196 is ethoxy.
  • L 10 is -C(H 2 )-. In some embodiments of compounds of Formula Ihh, further to any of the above embodiments of Formula Ihh, L 10 is -C(O)-.
  • L u is -C(H 2 )- or -C(0)-;
  • R 199 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally
  • R 201 is hydrogen and R 202 is hydrogen, fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; or
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; R 203 is fluoro or lower alkoxy optionally substitituted with one or more fluoro; and
  • R 204 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 199 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 199 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and Ci_ 3 alkoxy substituted with Ci_ 3 alkoxy.
  • R 199 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 202 is hydrogen and R 201 is lower alkyl optionally substituted with one or more fluoro.
  • compounds of Formula Iii further to any of the above
  • R is hydrogen and R is lower alkyl.
  • R 202 is hydrogen and R 201 is C 1 .3 alkyl.
  • R 202 is hydrogen and R 201 is methyl.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo.
  • R is hydrogen and R is fluoro, chloro, bromo.
  • R 201 is hydrogen and R 202 is cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 201 is hydrogen and R 202 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 201 is hydrogen and R 202 is cycloalkyl or Ci_ 3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R is hydrogen and R is cyclopropyl or Ci_3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 201 is hydrogen and R 202 is cyclopropyl, trifluoromethyl, methyl or ethyl.
  • R is hydrogen and R is cycloalkyl.
  • R 201 is hydrogen and R 202 is cyclopropyl.
  • R 201 is hydrogen and R 202 is lower alkyl optionally substituted with one or more fluoro.
  • R 201 is hydrogen and R 202 is Ci_ 3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 201 is hydrogen and R 202 is trifluoromethyl, methyl or ethyl.
  • R 201 is hydrogen and R 202 is trifluoromethyl. In some embodiments of compounds of Formula Iii, further to any of the above embodiments of Formula Iii, R 201 is hydrogen and R 202 is methyl. In some embodiments of compounds of Formula Iii, further to any of the above embodiments of Formula Iii,
  • R 201 is hydrogen and R 202 is ethyl.
  • R is hydrogen and R is lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is lower alkoxy.
  • R 201 is hydrogen and R 202 is C1.3 alkoxy.
  • R 202 is C1.3 alkoxy.
  • R is hydrogen and R is methoxy or ethoxy.
  • R is hydrogen and R is methoxy or ethoxy.
  • R is hydrogen and R is methoxy.
  • R is hydrogen and R is ethoxy.
  • L u is -C(H 2 )-.
  • Lu is -C(O)-.
  • R 205 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally
  • R is hydrogen and R is hydrogen, fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; or
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; R 208 is fluoro or lower alkoxy optionally substitituted with one or more fluoro; and
  • R 209 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 205 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 205 is selected from the group consisting of C3.6 cycloalkyl, C 1 .3 alkyl, C 1 .3 alkoxy, and C 1 .3 alkoxy substituted with C 1 .3 alkoxy.
  • R 205 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 20V is hydrogen and R206 is lower alkyl optionally substituted with one or more fluoro.
  • R 20V is hydrogen and R206 is lower alkyl.
  • R 207 is hydrogen and R 206 is Ci_3 alkyl.
  • R 20V is hydrogen and R206 is methyl.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo.
  • R 206 is hydrogen and R20V is cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 206 is hydrogen and R20V is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 206 is hydrogen and R20V is cycloalkyl or Ci_ 3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • compounds of Formula Ijj are hydrogen and R20V is cycloalkyl or Ci_ 3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R is hydrogen and R is cyclopropyl or Ci_3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 206 is hydrogen and R20V is cyclopropyl, trifluoromethyl, methyl or ethyl.
  • R 206 is hydrogen and R20V is cycloalkyl. In some embodiments of compounds of Formula Ijj, further to any of the above embodiments of Formula Ijj, R 206 is hydrogen and R 207 is cyclopropyl.
  • R 206 is hydrogen and R20V is lower alkyl optionally substituted with one or more fluoro. In some embodiments of compounds of Formula Ijj, further to any of the above embodiments of Formula Ijj, R 206 is hydrogen and R20V is C 1 .3 alkyl optionally substituted with 1, 2, or 3 fluoro. In some embodiments of compounds of Formula Ijj, further to any of the above embodiments of Formula Ijj, R 206 is hydrogen and R20V is trifluoromethyl, methyl or ethyl. In some embodiments of compounds of Formula Ijj, further to any of the above embodiments of Formula Ijj,
  • R 206 is hydrogen and R 20V is trifluoromethyl. In some embodiments of compounds of Formula Ijj, further to any of the above embodiments of Formula Ijj, R 206 is hydrogen and R 20V is methyl. In some embodiments of compounds of Formula Ijj, further to any of the above embodiments of Formula Ijj,
  • R 206 is hydrogen and R 20V is ethyl.
  • R 206 is hydrogen and R 20V is lower alkoxy optionally substituted with one or more fluoro.
  • R 20V is lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is lower alkoxy.
  • R 206 is hydrogen and R 207 is C 1 .3 alkoxy.
  • R 207 is C 1 .3 alkoxy.
  • R is hydrogen and R is methoxy or ethoxy.
  • R is hydrogen and R is methoxy or ethoxy.
  • R is hydrogen and R is methoxy.
  • R is hydrogen and R is ethoxy.
  • R 210 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally
  • R 211 is hydrogen and R 212 is hydrogen, fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; or
  • R 212 is hydrogen and R 211 is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; R 213 is fluoro or lower alkoxy optionally substitituted with one or more fluoro; and
  • R 214 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 210 is selected from the group consisting of C3.6 cycloalkyl, C1.3 alkyl, C1.3 alkoxy, and Ci_ 3 alkoxy substituted with Ci_ 3 alkoxy.
  • R 210 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • R 212 is hydrogen and R 211 is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 212 is hydrogen and R 211 is lower alkyl optionally substituted with one or more fluoro.
  • R 212 is hydrogen and R 211 is lower alkyl.
  • R 212 is hydrogen and R 211 is C1.3 alkyl. In some embodiments of compounds of Formula Ikk, further to any of the above embodiments of Formula Ikk, R 212 is hydrogen and R 211 is methyl.
  • R 211 is hydrogen and R 212 is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 211 is hydrogen and R 212 is fluoro, chloro, bromo.
  • R 211 is hydrogen and R 212 is cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 211 is hydrogen and R 212 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 211 is hydrogen and R 212 is cycloalkyl or C1.3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 211 is hydrogen and R 212 is cyclopropyl or Ci_3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 211 is hydrogen and R 212 is cyclopropyl, trifluoromethyl, methyl or ethyl.
  • R 211 is hydrogen and R 212 is cycloalkyl.
  • R 211 is hydrogen and R 212 is cyclopropyl.
  • R 211 is hydrogen and R 212 is lower alkyl optionally substituted with one or more fluoro.
  • R 211 is hydrogen and R 212 is C1.3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 211 is hydrogen and R 212 is trifluoromethyl, methyl or ethyl.
  • R 211 is hydrogen and R 212 is trifluoromethyl.
  • R 211 is hydrogen and R 212 is methyl. In some embodiments of compounds of Formula Ikk, further to any of the above embodiments of Formula Ikk, R 211 is hydrogen and R 212 is ethyl.
  • R 211 is hydrogen and R 212 is lower alkoxy optionally substituted with one or more fluoro. In some embodiments of compounds of Formula Ikk, further to any of the above embodiments of Formula Ikk, R 211 is hydrogen and R 212 is lower alkoxy. In some embodiments of compounds of Formula Ikk, further to any of the above embodiments of Formula Ikk, R 211 is hydrogen and R 212 is Ci_ 3 alkoxy. In some embodiments of compounds of Formula Ikk, further to any of the above embodiments of Formula Ikk, R 211 is hydrogen and R 212 is methoxy or ethoxy.
  • R 211 is hydrogen and R 212 is methoxy. In some embodiments of compounds of Formula Ikk, further to any of the above embodiments of Formula Ikk, R 211 is hydrogen and R 212 is ethoxy.
  • R 215 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally
  • R is hydrogen and R is hydrogen, fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; or
  • R 217 is hydrogen and R 216 is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; R 218 is fluoro or lower alkoxy optionally substitituted with one or more fluoro; and
  • R 219 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 215 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 215 is selected from the group consisting of C3.6 cycloalkyl, C1.3 alkyl, C1.3 alkoxy, and C1.3 alkoxy substituted with C1.3 alkoxy.
  • R 215 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • R 217 is hydrogen and R 216 is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 217 is hydrogen and R 216 is lower alkyl optionally substituted with one or more fluoro.
  • R 217 is hydrogen and R 216 is lower alkyl.
  • R 217 is hydrogen and R 216 is Ci_ 3 alkyl. In some embodiments of compounds of Formula Imm, further to any of the above embodiments of Formula Imm, R 217 is hydrogen and R 216 is methyl.
  • R 216 is hydrogen and R 217 is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 216 is hydrogen and R 217 is fluoro, chloro, bromo.
  • R 216 is hydrogen and R 217 is cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 216 is hydrogen and R 217 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 216 is hydrogen and R 217 is cycloalkyl or Ci_ 3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 216 is hydrogen and R 217 is cyclopropyl or Ci_3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 216 is hydrogen and R 217 is cyclopropyl, trifluoromethyl, methyl or ethyl.
  • R 216 is hydrogen and R 217 is cycloalkyl. In some embodiments of compounds of Formula Imm, further to any of the above embodiments of Formula Imm, R 216 is hydrogen and R 217 is cyclopropyl.
  • R 216 is hydrogen and R 217 is lower alkyl optionally substituted with one or more fluoro. In some embodiments of compounds of Formula Imm, further to any of the above embodiments of Formula Imm, R 216 is hydrogen and R 217 is C1.3 alkyl optionally substituted with 1, 2, or 3 fluoro. In some embodiments of compounds of Formula Imm, further to any of the above embodiments of Formula Imm, R 216 is hydrogen and R 217 is trifluoromethyl, methyl or ethyl.
  • R 216 is hydrogen and R 217 is trifluoromethyl. In some embodiments of compounds of Formula Imm, further to any of the above embodiments of Formula Imm, R 216 is hydrogen and R 217 is methyl. In some embodiments of compounds of Formula Imm, further to any of the above embodiments of Formula Imm, R 216 is hydrogen and R 217 is ethyl.
  • R 216 is hydrogen and R 217 is lower alkoxy optionally substituted with one or more fluoro. In some embodiments of compounds of Formula Imm, further to any of the above embodiments of Formula Imm, R 216 is hydrogen and R 217 is lower alkoxy. In some embodiments of compounds of Formula Imm, further to any of the above embodiments of Formula Imm, R 216 is hydrogen and R 217 is C1.3 alkoxy. In some embodiments of compounds of Formula Imm, further to any of the above embodiments of Formula Imm, R 216 is hydrogen and R 217 is methoxy or ethoxy.
  • R 216 is hydrogen and R 217 is methoxy. In some embodiments of compounds of Formula Imm, further to any of the above embodiments of Formula Imm, R 216 is hydrogen and R 217 is ethoxy.
  • R 220 is selected from the group consisting of hydrogen, cycloalkyl, lower alkyl optionally
  • R 221 is hydrogen and R 222 is hydrogen, fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; or
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; R 223 is fluoro or lower alkoxy optionally substitituted with one or more fluoro; and
  • R 224 is lower alkyl, lower alkyl substituted with one or more fluoro, or lower alkyl substituted with lower alkoxy.
  • R 220 is selected from the group consisting of cycloalkyl, lower alkyl, lower alkoxy, and lower alkoxy substituted with lower alkoxy.
  • R 220 is selected from the group consisting of C3.6 cycloalkyl, C1.3 alkyl, C1.3 alkoxy, and C1.3 alkoxy substituted with C1.3 alkoxy.
  • R 220 is selected from the group consisting of methyl, cyclopropyl, methoxy, ethoxy, and 2-methoxy-ethoxy.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 222 is hydrogen and R 221 is lower alkyl optionally substituted with one or more fluoro.
  • R 222 is hydrogen and R 221 is lower alkyl.
  • R 222 is hydrogen and R 221 is Ci_ 3 alkyl. In some embodiments of compounds of Formula Inn, further to any
  • R is hydrogen and R is methyl.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo.
  • R is hydrogen and R is fluoro, chloro, bromo.
  • R 221 is hydrogen and R 222 is cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 221 is hydrogen and R 222 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 221 is hydrogen and R 222 is cycloalkyl or C1.3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • compounds of Formula Inn are hydrogen and R 222 is cycloalkyl or C1.3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R is hydrogen and R is cyclopropyl or Ci_3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 221 is hydrogen and R 222 is cyclopropyl, trifluoromethyl, methyl or ethyl.
  • R 221 is hydrogen and R 222 is cycloalkyl. In some embodiments of compounds of Formula Inn, further to any of the above embodiments of Formula Inn, R 221 is hydrogen and R 222 is cyclopropyl.
  • R 221 is hydrogen and R 222 is lower alkyl optionally substituted with one or more fluoro.
  • R 221 is hydrogen and R 222 is Ci_ 3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 221 is hydrogen and R 222 is trifluoromethyl, methyl or ethyl.
  • R is hydrogen and R is trifluoromethyl.
  • R 221 is hydrogen and R 222 is methyl.
  • R 222 is methyl.
  • R 221 is hydrogen and R 222 is ethyl.
  • R 221 is hydrogen and R 222 is lower alkoxy optionally substituted with one or more fluoro.
  • R 222 is lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is lower alkoxy. In some embodiments of compounds of Formula Inn, further to any of the above embodiments of Formula Inn, R is hydrogen and R 222 is Ci_ 3 alkoxy. In some embodiments of compounds of Formula Inn, further to any
  • R is hydrogen and R is methoxy or ethoxy.
  • R is hydrogen and R is methoxy or ethoxy.
  • R is hydrogen and R is methoxy.
  • R is hydrogen and R is ethoxy.
  • R 225 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • R 22V is hydrogen and R 228 is hydrogen, fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; or
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 225 is hydrogen, chloro or lower alkyl.
  • R 225 is hydrogen, chloro or Ci_ 3 alkyl. In one embodiment, R 225 is hydrogen, chloro or methyl.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 228 is hydrogen and R 22V is lower alkyl optionally substituted with one or more fluoro.
  • compounds of Formula loo further to any of the above
  • R is hydrogen and R is lower alkyl.
  • R 228 is hydrogen and R is Ci_ 3 alkyl.
  • R is hydrogen and R is lower alkyl.
  • R is hydrogen and R is methyl.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo.
  • R is hydrogen and R is fluoro, chloro, bromo.
  • R 22V is hydrogen and R 228 is cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 22V is hydrogen and R 228 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 22V is hydrogen and R 228 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R is hydrogen and R is cycloalkyl or C1.3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R is hydrogen and R is cycloalkyl or C1.3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R is hydrogen and R is cyclopropyl or Ci_3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R is hydrogen and R is cyclopropyl, trifluoromethyl, methyl or ethyl.
  • R is hydrogen and R is cycloalkyl.
  • R 227 is hydrogen and R 228 is cyclopropyl.
  • R 22V is hydrogen and R 228 is lower alkyl optionally substituted with one or more fluoro.
  • R 22V is hydrogen and R 228 is C1.3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 22V is hydrogen and R 228 is C1.3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R is hydrogen and R is trifluoromethyl, methyl or ethyl.
  • R is hydrogen and R is trifluoromethyl, methyl or ethyl.
  • R is hydrogen and R is trifluoromethyl.
  • R is hydrogen and R is methyl.
  • R is hydrogen and R is methyl.
  • R 22V is hydrogen and R 228 is ethyl.
  • R is hydrogen and R is lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is lower alkoxy.
  • R 227 is hydrogen and R 228 is C 1 .3 alkoxy.
  • R 228 is C 1 .3 alkoxy.
  • R is hydrogen and R is methoxy or ethoxy.
  • R is hydrogen and R is methoxy or ethoxy.
  • R is hydrogen and R is methoxy.
  • R is hydrogen and R is ethoxy.
  • L i2 is -C(H 2 )-.
  • L 12 is -C(O)-.
  • R 229 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • R is hydrogen and R is hydrogen, fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; or
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro. [0307] In some embodiments of compounds of Formula Ipp, R is hydrogen, chloro or lower alkyl.
  • R 229 is hydrogen, chloro or Ci_ 3 alkyl. In one embodiment, R 229 is hydrogen, chloro or methyl.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 231 is hydrogen and R 230 is lower alkyl optionally substituted with one or more fluoro.
  • R 231 is hydrogen and R 230 is lower alkyl.
  • R 231 is hydrogen and R 230 is C1.3 alkyl.
  • R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is methyl.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo.
  • R is hydrogen and R is fluoro, chloro, bromo.
  • R 230 is hydrogen and R 231 is cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 230 is hydrogen and R 231 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 230 is hydrogen and R 231 is cycloalkyl or C1.3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R is hydrogen and R is cyclopropyl or Ci_3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 230 is hydrogen and R 231 is cyclopropyl, trifluoromethyl, methyl or ethyl.
  • R 230 is hydrogen and R 231 is cycloalkyl. In some embodiments of compounds of Formula Ipp, further to any of the above embodiments of Formula Ipp, R 230 is hydrogen and R 231 is cyclopropyl. [0312] In some embodiments of compounds of Formula Ipp, further to any of the above
  • R 230 is hydrogen and R 231 is lower alkyl optionally substituted with one or more fluoro.
  • R 230 is hydrogen and R 231 is Ci_ 3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 230 is hydrogen and R 231 is trifluoromethyl, methyl or ethyl.
  • R is hydrogen and R is trifluoromethyl.
  • R 230 is hydrogen and R 231 is methyl.
  • R 231 is methyl.
  • R 230 is hydrogen and R 231 is ethyl.
  • R 230 is hydrogen and R 231 is lower alkoxy optionally substituted with one or more fluoro.
  • R 230 is hydrogen and R 231 is lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is lower alkoxy.
  • R 230 is hydrogen and R 231 is Ci_ 3 alkoxy.
  • R 231 is Ci_ 3 alkoxy.
  • R is hydrogen and R is methoxy or ethoxy.
  • R is hydrogen and R is methoxy or ethoxy.
  • R is hydrogen and R is methoxy.
  • R is hydrogen and R is ethoxy.
  • R 232 is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • R 233 is hydrogen and R 234 is hydrogen, fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; or R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 232 is hydrogen, chloro or lower alkyl.
  • R 232 is hydrogen, chloro or Ci_ 3 alkyl. In one embodiment, R 232 is hydrogen, chloro or methyl.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 234 is hydrogen and R 233 is lower alkyl optionally substituted with one or more fluoro.
  • R 234 is hydrogen and R 233 is lower alkyl.
  • R 233 is C1.3 alkyl.
  • R is hydrogen and R is methyl.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo.
  • R is hydrogen and R is fluoro, chloro, bromo.
  • R 233 is hydrogen and R 234 is cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 233 is hydrogen and R 234 is cycloalkyl or lower alkyl optionally substituted with one or more fluoro.
  • R 233 is hydrogen and R 234 is cycloalkyl or C1.3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R is hydrogen and R is cyclopropyl or Ci_3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 233 is hydrogen and R 234 is cyclopropyl, trifluoromethyl, methyl or ethyl.
  • R 233 is hydrogen and R 234 is cycloalkyl. In some embodiments of compounds of Formula Iqq, further to any of the above embodiments of Formula Iqq, R 233 is hydrogen and R 234 is cyclopropyl.
  • R 233 is hydrogen and R 234 is lower alkyl optionally substituted with one or more fluoro.
  • R 233 is hydrogen and R 234 is C1.3 alkyl optionally substituted with 1, 2, or 3 fluoro.
  • R 233 is hydrogen and R 234 is trifluoromethyl, methyl or ethyl.
  • R is hydrogen and R is trifluoromethyl.
  • R 233 is hydrogen and R 234 is methyl.
  • R 234 is methyl.
  • R 233 is hydrogen and R 234 is ethyl.
  • R 233 is hydrogen and R 234 is lower alkoxy optionally substituted with one or more fluoro.
  • R 234 is lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is lower alkoxy.
  • R 233 is hydrogen and R 234 is Ci_ 3 alkoxy.
  • R 234 is Ci_ 3 alkoxy.
  • R is hydrogen and R is methoxy or ethoxy.
  • R is hydrogen and R is methoxy or ethoxy.
  • R is hydrogen and R is methoxy.
  • R is hydrogen and R is ethoxy.
  • R is hydrogen, fluoro, chloro, or lower alkyl optionally substitituted with one or more fluoro;
  • R 236 is hydrogen and R 237 is hydrogen, fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro; or
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 235 is hydrogen, chloro or lower alkyl.
  • R 235 is hydrogen, chloro or C1.3 alkyl. In one embodiment, R 235 is hydrogen, chloro or methyl.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R 23V is hydrogen and R 236 is lower alkyl optionally substituted with one or more fluoro.
  • compounds of Formula Irr further to any of the above
  • R is hydrogen and R is lower alkyl.
  • R 237 is hydrogen and R 236 is d.3 alkyl.
  • R 23V is hydrogen and R 236 is methyl.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.
  • R is hydrogen and R is fluoro, chloro, bromo, cycloalkyl, lower alkyl optionally substituted with one or more fluoro, or lower alkoxy optionally substituted with one or more fluoro.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/US2011/033192 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor Ceased WO2011133637A2 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
ES11772612.5T ES2641643T3 (es) 2010-04-21 2011-04-20 Compuestos y métodos para la modulación de quinasas, e indicaciones de los mismos
NZ603087A NZ603087A (en) 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor
HRP20171660TT HRP20171660T1 (hr) 2010-04-21 2011-04-20 Spojevi i postupci za modulaciju kinaze, te indikacije za njih
CN201180030925.5A CN102947305B (zh) 2010-04-21 2011-04-20 用于激酶调节的化合物和方法及其适应症
EA201290973A EA028105B1 (ru) 2010-04-21 2011-04-20 Соединения и способы модулирования киназ и показания по их применению
AU2011242778A AU2011242778B2 (en) 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor
PH1/2012/502103A PH12012502103A1 (en) 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor
GEAP201112896A GEP20156251B (en) 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor
EP11772612.5A EP2560972B1 (en) 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor
MX2012012197A MX336056B (es) 2010-04-21 2011-04-20 Compuestos y metodos para la modulacion de quinasa e indicaciones de la misma.
LTEP11772612.5T LT2560972T (lt) 2010-04-21 2011-04-20 Kinazės moduliavimui skirti junginiai ir būdai bei jų indikacijos
SI201131348T SI2560972T1 (sl) 2010-04-21 2011-04-20 Spojine in postopki za kinazno modulacijo in indikacije za to
DK11772612.5T DK2560972T3 (da) 2010-04-21 2011-04-20 Forbindelser og fremgangsmåder til kinasemodulering og indikationer hertil
SM20170458T SMT201700458T1 (it) 2010-04-21 2011-04-20 Composti e metodi per modulazione di chinasi, e loro indicazioni
KR1020127030470A KR101799126B1 (ko) 2010-04-21 2011-04-20 키나아제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
SG2012076584A SG184874A1 (en) 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor
RS20171089A RS56588B1 (sr) 2010-04-21 2011-04-20 Jedinjenja i postupci za modulaciju kinaze i njenih indikacija
JP2013506264A JP5808793B2 (ja) 2010-04-21 2011-04-20 キナーゼ調節のための化合物および方法、ならびにそれらの適応症
CA2796998A CA2796998C (en) 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor
UAA201212061A UA109128C2 (ru) 2010-04-21 2011-04-20 Соединения и способ модулирования киназ и показания к их применению
BR112012026927A BR112012026927A2 (pt) 2010-04-21 2011-04-20 composto e métodos para modulação de cinase, e indicações para os mesmos.
PL11772612T PL2560972T3 (pl) 2010-04-21 2011-04-20 Związki i sposoby do modulacji kinazy i ich wskazania
MA35365A MA34229B1 (fr) 2010-04-21 2011-04-20 Compositions et méthodes de modulation des kinases et leurs indications
IL222498A IL222498A (en) 2010-04-21 2012-10-17 Compounds and methods for kinase modulation and indications therefor
ZA2012/07898A ZA201207898B (en) 2010-04-21 2012-10-19 Compounds and methods for kinase modulation,and indications therefor
CY20171101332T CY1120554T1 (el) 2010-04-21 2017-12-19 Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32662610P 2010-04-21 2010-04-21
US61/326,626 2010-04-21

Publications (2)

Publication Number Publication Date
WO2011133637A2 true WO2011133637A2 (en) 2011-10-27
WO2011133637A3 WO2011133637A3 (en) 2012-02-09

Family

ID=44816304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/033192 Ceased WO2011133637A2 (en) 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor

Country Status (39)

Country Link
US (3) US8901118B2 (enExample)
EP (1) EP2560972B1 (enExample)
JP (2) JP5808793B2 (enExample)
KR (1) KR101799126B1 (enExample)
CN (1) CN102947305B (enExample)
AR (2) AR080940A1 (enExample)
AU (1) AU2011242778B2 (enExample)
BR (1) BR112012026927A2 (enExample)
CA (1) CA2796998C (enExample)
CL (1) CL2012002937A1 (enExample)
CO (1) CO6620045A2 (enExample)
CR (1) CR20120536A (enExample)
CY (1) CY1120554T1 (enExample)
DK (1) DK2560972T3 (enExample)
EA (1) EA028105B1 (enExample)
EC (1) ECSP12012245A (enExample)
ES (1) ES2641643T3 (enExample)
GE (1) GEP20156251B (enExample)
HR (1) HRP20171660T1 (enExample)
HU (1) HUE036461T2 (enExample)
IL (1) IL222498A (enExample)
LT (1) LT2560972T (enExample)
MA (1) MA34229B1 (enExample)
MX (1) MX336056B (enExample)
MY (1) MY160780A (enExample)
NZ (2) NZ603087A (enExample)
PE (1) PE20130240A1 (enExample)
PH (1) PH12012502103A1 (enExample)
PL (1) PL2560972T3 (enExample)
PT (1) PT2560972T (enExample)
RS (1) RS56588B1 (enExample)
SG (2) SG10201505606QA (enExample)
SI (1) SI2560972T1 (enExample)
SM (1) SMT201700458T1 (enExample)
TW (2) TWI619713B (enExample)
UA (1) UA109128C2 (enExample)
UY (1) UY33346A (enExample)
WO (1) WO2011133637A2 (enExample)
ZA (1) ZA201207898B (enExample)

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012137089A1 (en) 2011-04-05 2012-10-11 Pfizer Limited Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases
WO2014053968A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
WO2014053967A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
WO2014053965A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Tropomyosin-related kinase inhibitors
WO2015017533A1 (en) 2013-07-30 2015-02-05 Blueprint Medicines Corporation Ntrk2 fusions
EP2709622A4 (en) * 2011-05-17 2015-03-04 Plexxikon Inc CINEMA MODULATION AND INDICATIONS THEREFOR
WO2015092610A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2015159175A1 (en) 2014-04-15 2015-10-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9505765B2 (en) 2012-07-26 2016-11-29 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment
WO2016196671A1 (en) 2015-06-01 2016-12-08 Loxo Oncology, Inc. Methods of diagnosing and treating cancer
WO2017011776A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2017075107A1 (en) 2015-10-26 2017-05-04 Nanda Nisha Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US9663517B2 (en) 2009-04-03 2017-05-30 Plexxikon Inc. Compositions and uses thereof
US9718822B2 (en) 2010-05-20 2017-08-01 Array Biopharma, Inc. Macrocyclic compounds as Trk kinase inhibitors
US9782414B2 (en) 2014-11-16 2017-10-10 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US9782415B2 (en) 2009-07-09 2017-10-10 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
WO2017176744A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Methods of treating pediatric cancers
WO2017176751A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US9795611B2 (en) 2008-09-22 2017-10-24 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
WO2018071454A1 (en) 2016-10-10 2018-04-19 Andrews Steven W Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2018071447A1 (en) 2016-10-10 2018-04-19 Andrews Steven W Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10005783B2 (en) 2008-10-22 2018-06-26 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
WO2018170381A1 (en) 2017-03-16 2018-09-20 Andrews Steven W Macrocyclic compounds as ros1 kinase inhibitors
US10150783B2 (en) 2015-01-23 2018-12-11 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
WO2019075114A1 (en) 2017-10-10 2019-04-18 Mark Reynolds FORMULATIONS COMPRISING 6- (2-HYDROXY-2-METHYLPROPOXY) -4- (6- (6 - ((6-METHOXYPYRIDIN-3-YL) METHYL) -3,6-DIAZABICYCLO [3.1.1] HEPTAN-3- YL) PYRIDIN-3-YL) PYRAZOLO [1,5-A] pYRIDINE-3-carbonitrile
WO2019075108A1 (en) 2017-10-10 2019-04-18 Metcalf Andrew T CRYSTALLINE FORMS
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
WO2020028258A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
US10981908B2 (en) 2017-02-01 2021-04-20 Phenex Pharmaceuticals Ag Aryl hydrocarbon receptor (AHR) modulator compounds
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
US11091486B2 (en) 2016-10-26 2021-08-17 Array Biopharma, Inc Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
US11192936B2 (en) 2014-01-10 2021-12-07 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
US11214571B2 (en) 2016-05-18 2022-01-04 Array Biopharma Inc. Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
US11376241B2 (en) 2017-02-01 2022-07-05 Phenex Pharmaceuticals Ag Aryl hydrocarbon receptor (AhR) modulator compounds
CN114920744A (zh) * 2021-11-16 2022-08-19 中国药科大学 一种非共价btk激酶抑制剂及其生物用途
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
US11897889B2 (en) 2020-08-18 2024-02-13 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
US11905292B2 (en) 2020-08-18 2024-02-20 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
US12030925B2 (en) 2018-05-18 2024-07-09 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP4480949A4 (en) * 2022-03-25 2025-06-18 Jumbo Drug Bank Co., Ltd. Crystal form of 1h-pyrrolo[2,3-c]pyridine compound and preparation method therefor

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
MX2012005284A (es) 2009-11-06 2012-06-28 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello.
CN102740698A (zh) 2009-11-18 2012-10-17 普莱希科公司 用于激酶调节的化合物和方法及其适应症
BR112012015745A2 (pt) 2009-12-23 2016-05-17 Plexxikon Inc compostos e métodos para a modulação de quinase, e indicações dos mesmos
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
WO2014039714A2 (en) 2012-09-06 2014-03-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2895239C (en) 2012-12-21 2020-10-27 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2014145051A1 (en) 2013-03-15 2014-09-18 Jiazhong Zhang Heterocyclic compounds and uses thereof
BR112015028845A2 (pt) 2013-05-30 2017-07-25 Plexxikon Inc compostos para a modulação da quinase e indicações da mesma
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2016044067A1 (en) 2014-09-15 2016-03-24 Plexxikon Inc. Heterocyclic compounds and uses thereof
US20180263945A1 (en) * 2014-12-19 2018-09-20 Research Institute At Nationwide Children's Hospital Pyruvate compounds for treatment of peripheral neuropathy
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
BR112017023540B1 (pt) 2015-05-06 2023-04-04 Plexxikon, Inc. Processos de preparação de derivados de 1h-pirrolo[2,3-b]piridina que modulam quinases
HRP20201383T1 (hr) 2015-05-06 2020-11-27 Plexxikon Inc. Kruti oblici spoja za moduliranje kinaza
US10316032B2 (en) 2015-05-22 2019-06-11 Plexxikon Inc. Solid forms of a compound for modulating kinases
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3353179B1 (en) 2015-09-21 2022-02-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2017100201A1 (en) 2015-12-07 2017-06-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2904615T3 (es) 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
EP3454860B1 (en) * 2016-05-11 2025-09-17 Beta Pharma, Inc. 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
US20180153922A1 (en) 2016-12-06 2018-06-07 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
WO2018136202A2 (en) 2016-12-23 2018-07-26 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
CA3056777A1 (en) 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
TWI805599B (zh) 2017-07-25 2023-06-21 美商第一三共公司 激酶調節化合物之調配物
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
TWI803530B (zh) 2017-10-27 2023-06-01 美商普雷辛肯公司 調節激酶之化合物之調配物
WO2019157119A1 (en) * 2018-02-07 2019-08-15 University Of Cincinnati System and method for detecting small blood-tissue barrier disruption
WO2019183145A1 (en) 2018-03-20 2019-09-26 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
KR102129114B1 (ko) * 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
CN110833557A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗肾小管肾炎的用途
CN110833552A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
EP3841098A4 (en) 2018-08-22 2022-05-04 Cullgen (Shanghai), Inc. TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHOD OF USE
AU2020271836B2 (en) 2019-04-09 2025-11-13 Opna Bio SA Condensed azines for EP300 or CBP modulation and indications therefor
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
CN115697989B (zh) 2020-02-26 2025-03-18 上海睿跃生物科技有限公司 原肌球蛋白受体激酶(trk)降解化合物和使用方法
AU2021261383A1 (en) 2020-04-23 2022-11-17 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
EP4143168A1 (en) 2020-04-29 2023-03-08 Plexxikon Inc. Synthesis of heterocyclic compounds
JP2023542473A (ja) 2020-08-21 2023-10-10 プレキシコン インコーポレーテッド 併用薬抗がん治療
KR20230058134A (ko) * 2020-09-25 2023-05-02 점보 드러그 뱅크 컴퍼니 리미티드 1H-피롤로[2,3-c]피리딘계 화합물 및 이의 용도
WO2025244944A1 (en) * 2024-05-20 2025-11-27 Opna Bio SA Crystal forms of an agent

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
SK17342002A3 (sk) 2000-06-26 2004-06-08 Pfizer Products Inc. Derivát pyrolo[2,3-d]pyrimidínu ako činidlo potlačujúce imunitu
GB0107368D0 (en) * 2001-03-23 2001-05-16 Novartis Ag Organic compounds
WO2002092087A1 (en) 2001-05-11 2002-11-21 Vertex Pharmaceuticals Incorporated 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
CN101001857B (zh) 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
US20040171062A1 (en) 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
EP1558751A4 (en) 2002-09-16 2007-08-22 Plexxikon Inc CRYSTALLINE STRUCTURE OF PROTEIN KINASE PIM-1
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
US20050048573A1 (en) 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
SE0300456D0 (sv) 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
JP2007524374A (ja) 2003-02-28 2007-08-30 プレキシコン，インコーポレーテッド Ｐｙｋ２結晶構造および使用
US20050079548A1 (en) 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
DK1648889T3 (da) 2003-07-11 2009-01-05 Warner Lambert Co Isethionatsalt af en selektiv CDK4-inhibitor
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
WO2005009958A1 (en) 2003-07-17 2005-02-03 Plexxikon, Inc. Ppar active compounds
US20050164300A1 (en) 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US7517970B2 (en) 2003-12-19 2009-04-14 Plexxikon, Inc. Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
US7504509B2 (en) 2003-12-19 2009-03-17 Plexxikon, Inc. Compounds and methods for development of Ret modulators
ES2424642T3 (es) * 2004-02-14 2013-10-07 Irm Llc Compuestos y composiciones como inhibidores de la proteína quinasa
JP4866723B2 (ja) * 2004-02-26 2012-02-01 協和発酵キリン株式会社 好中球性炎症疾患の予防及び／または治療剤
CA2565965A1 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
WO2005116035A1 (en) 2004-05-27 2005-12-08 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
US20060058339A1 (en) 2004-06-17 2006-03-16 Ibrahim Prabha N Compounds modulating c-kit activity and uses therefor
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
CA2583428A1 (en) 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
CA2589896A1 (en) 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
AU2005311925A1 (en) 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR PPAR active compounds
US20060160135A1 (en) 2004-12-08 2006-07-20 Weiru Wang SF-1 and LRH-1 modulator development
CN101223169A (zh) * 2005-05-17 2008-07-16 普莱希科公司 吡咯并[2,3-b]吡啶衍生物蛋白激酶抑制剂
WO2007013896A2 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
TWI473808B (zh) 2005-06-22 2015-02-21 Plexxikon Inc 用於激酶調節的化合物及方法及其適應症
CN101304992A (zh) 2005-09-07 2008-11-12 普莱希科公司 用作ppar调节剂的1,3-二取代吲哚衍生物
JP2009507846A (ja) 2005-09-07 2009-02-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
US20080234349A1 (en) 2005-09-07 2008-09-25 Jack Lin PPAR active compounds
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
JP2010514695A (ja) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法およびそのための適応症
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
JP2010520303A (ja) 2007-03-08 2010-06-10 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
EP2148875A1 (en) * 2007-05-04 2010-02-03 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CL2009000400A1 (es) * 2008-02-22 2010-09-10 Irm Llc Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras.
WO2009115084A2 (de) 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009152087A1 (en) 2008-06-10 2009-12-17 Plexxikon, Inc. Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor
CN104530052A (zh) 2008-06-10 2015-04-22 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
TR201807039T4 (tr) 2008-10-22 2018-06-21 Array Biopharma Inc Trk kinaz inhibitörleri olarak sübstitüe edilmiş pirazolo[1,5-]pirimidin bileşikleri.
KR101663339B1 (ko) 2009-03-11 2016-10-06 플렉시콘 인코퍼레이티드 Ｒａｆ 키나제의 억제를 위한 피롤로［２,３-ｂ］피리딘 유도체
CN102421775A (zh) 2009-03-11 2012-04-18 普莱希科公司 抑制Raf激酶的吡咯并[2，3-b]吡啶衍生物
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
MX2011011735A (es) 2009-05-04 2011-11-29 Plexxikon Inc Compuestos y metodos para la inhibicion de renina, e indicaciones para ello.
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MX2012005284A (es) 2009-11-06 2012-06-28 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello.
CN102740698A (zh) 2009-11-18 2012-10-17 普莱希科公司 用于激酶调节的化合物和方法及其适应症
BR112012015745A2 (pt) 2009-12-23 2016-05-17 Plexxikon Inc compostos e métodos para a modulação de quinase, e indicações dos mesmos
TWI619713B (zh) * 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US8642606B2 (en) 2010-09-29 2014-02-04 Plexxikon Inc. ZAP-70 active compounds
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
SG194847A1 (en) 2011-05-17 2013-12-30 Plexxikon Inc Kinase modulation and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014039714A2 (en) 2012-09-06 2014-03-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2895239C (en) 2012-12-21 2020-10-27 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014145051A1 (en) 2013-03-15 2014-09-18 Jiazhong Zhang Heterocyclic compounds and uses thereof
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
BR112015028845A2 (pt) 2013-05-30 2017-07-25 Plexxikon Inc compostos para a modulação da quinase e indicações da mesma
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None
See also references of EP2560972A4

Cited By (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US10011604B2 (en) 2008-09-22 2018-07-03 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US9796723B2 (en) 2008-09-22 2017-10-24 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US10590139B2 (en) 2008-09-22 2020-03-17 Array Biopharma Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US9795611B2 (en) 2008-09-22 2017-10-24 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US10774085B2 (en) 2008-10-22 2020-09-15 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
US10047097B2 (en) 2008-10-22 2018-08-14 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US11267818B2 (en) 2008-10-22 2022-03-08 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US10005783B2 (en) 2008-10-22 2018-06-26 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US9663517B2 (en) 2009-04-03 2017-05-30 Plexxikon Inc. Compositions and uses thereof
US9782415B2 (en) 2009-07-09 2017-10-10 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US10251889B2 (en) 2009-07-09 2019-04-09 Array BioPharm Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US10758542B2 (en) 2009-07-09 2020-09-01 Array Biopharma Inc. Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors
US9796724B2 (en) 2009-07-09 2017-10-24 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US9840519B2 (en) 2010-05-20 2017-12-12 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
US9750744B2 (en) 2010-05-20 2017-09-05 Array Biopharma, Inc. Macrocyclic compounds as Trk kinase inhibitors
US9902741B2 (en) 2010-05-20 2018-02-27 Array Biopharma Inc. Macrocyclic compounds as TRK kinase inhibitors
US9718822B2 (en) 2010-05-20 2017-08-01 Array Biopharma, Inc. Macrocyclic compounds as Trk kinase inhibitors
US10647730B2 (en) 2010-05-20 2020-05-12 Array Biopharma Inc. Macrocyclic compounds as TRK kinase inhibitors
US11337976B2 (en) 2011-02-07 2022-05-24 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US12076322B2 (en) 2011-02-07 2024-09-03 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2012137089A1 (en) 2011-04-05 2012-10-11 Pfizer Limited Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases
US9550768B2 (en) 2011-05-17 2017-01-24 Plexxikon Inc. Kinase modulation and indications therefor
EP2709622A4 (en) * 2011-05-17 2015-03-04 Plexxikon Inc CINEMA MODULATION AND INDICATIONS THEREFOR
US9730918B2 (en) 2012-03-19 2017-08-15 Plexxikon Inc. Kinase modulation, and indications therefor
US10123998B2 (en) 2012-03-19 2018-11-13 Plexxikon Inc. Kinase modulation, and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9695169B2 (en) 2012-05-31 2017-07-04 Plexxikon Inc. Synthesis of heterocyclic compounds
US9505765B2 (en) 2012-07-26 2016-11-29 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment
WO2014053968A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
WO2014053967A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
WO2014053965A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Tropomyosin-related kinase inhibitors
WO2015017533A1 (en) 2013-07-30 2015-02-05 Blueprint Medicines Corporation Ntrk2 fusions
EP3628749A1 (en) 2013-07-30 2020-04-01 Blueprint Medicines Corporation Ntrk2 fusions
US10407509B2 (en) 2013-07-30 2019-09-10 Blueprint Medicines Corporation NTRK2 fusions
WO2015092610A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
US11192936B2 (en) 2014-01-10 2021-12-07 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
WO2015159175A1 (en) 2014-04-15 2015-10-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
US10813936B2 (en) 2014-11-16 2020-10-27 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US9782414B2 (en) 2014-11-16 2017-10-10 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10799505B2 (en) 2014-11-16 2020-10-13 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10285993B2 (en) 2014-11-16 2019-05-14 Array Biopharma Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10172861B2 (en) 2014-11-16 2019-01-08 Array Biopharma Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10150783B2 (en) 2015-01-23 2018-12-11 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
WO2016196671A1 (en) 2015-06-01 2016-12-08 Loxo Oncology, Inc. Methods of diagnosing and treating cancer
EP3722441A1 (en) 2015-06-01 2020-10-14 Loxo Oncology Inc. Method of diagnosing a cancer for a treatment with a trk inhibitor
US10023570B2 (en) 2015-07-16 2018-07-17 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US10138243B2 (en) 2015-07-16 2018-11-27 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
US10174027B2 (en) 2015-07-16 2019-01-08 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
US10174028B2 (en) 2015-07-16 2019-01-08 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
WO2017011776A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10907215B2 (en) 2015-10-26 2021-02-02 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10655186B2 (en) 2015-10-26 2020-05-19 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
WO2017075107A1 (en) 2015-10-26 2017-05-04 Nanda Nisha Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10724102B2 (en) 2015-10-26 2020-07-28 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10378068B2 (en) 2015-10-26 2019-08-13 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10370727B2 (en) 2015-10-26 2019-08-06 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10245263B2 (en) 2015-12-23 2019-04-02 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US10933065B2 (en) 2015-12-23 2021-03-02 Arqule Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US11020400B2 (en) 2015-12-23 2021-06-01 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US10137127B2 (en) 2016-04-04 2018-11-27 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10668072B2 (en) 2016-04-04 2020-06-02 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US11484535B2 (en) 2016-04-04 2022-11-01 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
WO2017176744A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Methods of treating pediatric cancers
WO2017176751A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
US10588908B2 (en) 2016-04-04 2020-03-17 Loxo Oncology, Inc. Methods of treating pediatric cancers
US11191766B2 (en) 2016-04-04 2021-12-07 Loxo Oncology, Inc. Methods of treating pediatric cancers
US11214571B2 (en) 2016-05-18 2022-01-04 Array Biopharma Inc. Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
US11020398B2 (en) 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
US11998545B2 (en) 2016-10-10 2024-06-04 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
US10112942B2 (en) 2016-10-10 2018-10-30 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US10172845B2 (en) 2016-10-10 2019-01-08 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US10172851B2 (en) 2016-10-10 2019-01-08 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US10137124B2 (en) 2016-10-10 2018-11-27 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
EP4144735A1 (en) 2016-10-10 2023-03-08 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10144734B2 (en) 2016-10-10 2018-12-04 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
WO2018071454A1 (en) 2016-10-10 2018-04-19 Andrews Steven W Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10441581B2 (en) 2016-10-10 2019-10-15 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US11648243B2 (en) 2016-10-10 2023-05-16 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US10555944B2 (en) 2016-10-10 2020-02-11 Eli Lilly And Company Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US10953005B1 (en) 2016-10-10 2021-03-23 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
EP3753939A1 (en) 2016-10-10 2020-12-23 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10881652B2 (en) 2016-10-10 2021-01-05 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
WO2018071447A1 (en) 2016-10-10 2018-04-19 Andrews Steven W Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US11091486B2 (en) 2016-10-26 2021-08-17 Array Biopharma, Inc Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
US11851434B2 (en) 2017-01-18 2023-12-26 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
US10981908B2 (en) 2017-02-01 2021-04-20 Phenex Pharmaceuticals Ag Aryl hydrocarbon receptor (AHR) modulator compounds
US11376241B2 (en) 2017-02-01 2022-07-05 Phenex Pharmaceuticals Ag Aryl hydrocarbon receptor (AhR) modulator compounds
US10688100B2 (en) 2017-03-16 2020-06-23 Array Biopharma Inc. Macrocylic compounds as ROS1 kinase inhibitors
US10966985B2 (en) 2017-03-16 2021-04-06 Array Biopharma Inc. Macrocyclic compounds as ROS1 kinase inhibitors
WO2018170381A1 (en) 2017-03-16 2018-09-20 Andrews Steven W Macrocyclic compounds as ros1 kinase inhibitors
WO2019075114A1 (en) 2017-10-10 2019-04-18 Mark Reynolds FORMULATIONS COMPRISING 6- (2-HYDROXY-2-METHYLPROPOXY) -4- (6- (6 - ((6-METHOXYPYRIDIN-3-YL) METHYL) -3,6-DIAZABICYCLO [3.1.1] HEPTAN-3- YL) PYRIDIN-3-YL) PYRAZOLO [1,5-A] pYRIDINE-3-carbonitrile
WO2019075108A1 (en) 2017-10-10 2019-04-18 Metcalf Andrew T CRYSTALLINE FORMS
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
US12030925B2 (en) 2018-05-18 2024-07-09 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
WO2020028258A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
US11897889B2 (en) 2020-08-18 2024-02-13 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
US11905292B2 (en) 2020-08-18 2024-02-20 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
US12428426B2 (en) 2020-08-18 2025-09-30 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
US12479851B2 (en) 2020-08-18 2025-11-25 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
CN114920744B (zh) * 2021-11-16 2024-05-07 中国药科大学 一种非共价btk激酶抑制剂及其生物用途
CN114920744A (zh) * 2021-11-16 2022-08-19 中国药科大学 一种非共价btk激酶抑制剂及其生物用途
EP4480949A4 (en) * 2022-03-25 2025-06-18 Jumbo Drug Bank Co., Ltd. Crystal form of 1h-pyrrolo[2,3-c]pyridine compound and preparation method therefor
AU2023238511B2 (en) * 2022-03-25 2025-11-27 Jumbo Drug Bank Co., Ltd. Crystal form of 1h-pyrrolo[2,3-c]pyridine compound and preparation method therefor

Also Published As

Publication number Publication date
AR115233A2 (es) 2020-12-09
MY160780A (en) 2017-03-15
EP2560972A2 (en) 2013-02-27
US20170283423A1 (en) 2017-10-05
CN102947305A (zh) 2013-02-27
TWI619713B (zh) 2018-04-01
TW201544506A (zh) 2015-12-01
US9682981B2 (en) 2017-06-20
NZ703538A (en) 2016-11-25
JP2016028073A (ja) 2016-02-25
ES2641643T3 (es) 2017-11-10
KR101799126B1 (ko) 2017-11-17
DK2560972T3 (da) 2017-11-27
US20110263595A1 (en) 2011-10-27
US20150183793A1 (en) 2015-07-02
SI2560972T1 (sl) 2017-12-29
PE20130240A1 (es) 2013-03-04
SG184874A1 (en) 2012-11-29
EA201290973A1 (ru) 2013-04-30
JP2013525363A (ja) 2013-06-20
JP5808793B2 (ja) 2015-11-10
EP2560972A4 (en) 2013-11-20
WO2011133637A3 (en) 2012-02-09
CY1120554T1 (el) 2019-07-10
TW201136929A (en) 2011-11-01
IL222498A (en) 2016-10-31
TWI510487B (zh) 2015-12-01
CN102947305B (zh) 2016-07-06
GEP20156251B (en) 2015-02-25
CR20120536A (es) 2013-02-01
KR20130066621A (ko) 2013-06-20
MX2012012197A (es) 2012-12-17
PH12012502103A1 (en) 2016-04-01
UA109128C2 (ru) 2015-07-27
AU2011242778A1 (en) 2012-11-22
CA2796998A1 (en) 2011-10-27
ZA201207898B (en) 2016-09-28
PL2560972T3 (pl) 2018-01-31
SG10201505606QA (en) 2015-08-28
NZ603087A (en) 2015-01-30
AR080940A1 (es) 2012-05-16
UY33346A (es) 2011-10-31
AU2011242778B2 (en) 2015-09-03
CA2796998C (en) 2019-03-05
RS56588B1 (sr) 2018-02-28
CO6620045A2 (es) 2013-02-15
EP2560972B1 (en) 2017-09-20
ECSP12012245A (es) 2012-11-30
SMT201700458T1 (it) 2017-11-15
PT2560972T (pt) 2017-10-09
BR112012026927A2 (pt) 2017-10-10
US8901118B2 (en) 2014-12-02
CL2012002937A1 (es) 2013-01-25
MX336056B (es) 2016-01-07
HRP20171660T1 (hr) 2017-12-15
EA028105B1 (ru) 2017-10-31
MA34229B1 (fr) 2013-05-02
LT2560972T (lt) 2017-10-25
HUE036461T2 (hu) 2018-07-30

Similar Documents

Publication Publication Date Title
US8901118B2 (en) Compounds and methods for kinase modulation, and indications therefor
AU2010315126B2 (en) Compounds and methods for kinase modulation, and indications therefor
EP2501236B1 (en) N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
AU2014233437A1 (en) Heterocyclic compounds and uses thereof
EP2516438A2 (en) Compounds and methods for kinase modulation, and indications therefor
HK1182382B (en) Compounds and methods for kinase modulation, and indications therefor
HK1182382A (en) Compounds and methods for kinase modulation, and indications therefor
HK1176238B (en) N-[2-fluoro-3-(4-amino-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4 benzenesulfonamid e derivatives as raf protein kinase modulators for the treatment of cancer
HK1176238A (en) N-[2-fluoro-3-(4-amino-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4 benzenesulfonamid e derivatives as raf protein kinase modulators for the treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180030925.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11772612

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2796998

Country of ref document: CA

Ref document number: 2013506264

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012002937

Country of ref document: CL

Ref document number: 9005/CHENP/2012

Country of ref document: IN

Ref document number: 002054-2012

Country of ref document: PE

Ref document number: CR2012-000536

Country of ref document: CR

Ref document number: 12012502103

Country of ref document: PH

Ref document number: MX/A/2012/012197

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1201005548

Country of ref document: TH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12187143

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 201290973

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 12896

Country of ref document: GE

REEP Request for entry into the european phase

Ref document number: 2011772612

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011772612

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: A201212061

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 20127030470

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011242778

Country of ref document: AU

Date of ref document: 20110420

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012026927

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012026927

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20121019